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endoscopy and clinic sessions, to the review of these patients, Dr Boyd
was first author but has kindly given me permission to quote this work.
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centre during the drafting of the paper for publication. The section on
the use of omeprazole for refractory ulcer was also based upon a three-
centre trial - two centres in Holland and one centre, for which I was
responsible, in Dundee and the project was supervised by Prof GNJ
Tytgat. The section on mucosal prostaglandin content and the review of
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1 INTRODUCTION
1.1 Epidemiology
Duodenal ulcer, for the purposes of these studies, is defined as a
breach in the duodenal mucosa, which extends through the muscularis
mucosa (189). Estimating the incidence of duodenal ulceration within a
given population is fraught with difficulty: ulcers may be asymptomatic
(56); the patient may tolerate the symptoms or treat him/herself with
over-the-counter medication; the general practitioner may treat without
investigation to confirm the diagnosis; or the patient may be either
inadequately documented or inadequately investigated on referral to a
hospital specialist.
1.1.1 Disease Markers
The criteria for estimation of ulcer disease within the population
has also varied considerably - the incidence of surgical procedures for
ulcer; the rate of hospital admissions and discharges for perforation;
the death rate from peptic ulcer; and evidence of ulceration at autopsy
have all been utilised (231,418,120,339,404,190). Geographical varia
tions in annual incidence makes comparison, not only between countries
but also between regions, difficult to interpret. In the UK, for
example, duodenal ulcer incidence decreases from North to South (228)
but in Norway (287) and India (228), as one travels in a northerly
direction, ulcer incidence decreases.
In Europe one of the most exhaustive and prospective studies has
been based on findings at autopsy in Leeds (404), with estimates of the
incidence of duodenal ulceration in males over the age of 35 years of
one in ten. This estimate is of the same order as in the necropsy
analysis by Ivy from the United States in the same period (190). In women,
however, ulcers were found in only one person in sixteen.
1.1.2 Time-trends
As duodenal ulceration is a chronic disease, cross-sectional
studies of the same region at different time periods will almost
certainly include many of the same individuals on many occasions. If the
rate of death of patients with duodenal ulcer disease were unchanged
over the decades, any alteration in the total population with ulcers
would be a true reflection of changes in the number of patients
acquiring the disease. Although that assumption is not true, estimates
can be made both from changes in the total population number and from
changes in the death rate. One is still left, however, with the problem
that the disease may last a variable length of time, the average of
which in a population may change from decade to decade. The proportion
of "new" cases in any cross-sectional study may therefore be different
from one decade to the next Changes in the occurrence of the disease
during a period of time are best assessed from studies based on new
cases, both in hospital and general practice. The earliest study of this
type was published by Doll in 1951 (97).
Hansen (156) noted a six fold increase in the number of patients
hospitalised in Copenhagen during the first thirty five years of this
century. Fig 1.1 I is adapted from an excellent review article by
Bonnevie (287) and depicts a three fold rise in the incidence of
perforated ulcers in Scotland during the 25 years from 1924 but, when
the figures for 1970 and 1975 are viewed in the context of the preceding
two decades, it seems likely that the value for 1968 is spuriously high
and there has, in fact, been little change from 1950. These data are
generated from several separate studies (183,193,245,341).
If time-trends are to be meaningfully examined then prospective or
repeated cross-sectional studies of a geographically well-defined
population are required. Only a few studies accommodate these criteria.
In York, there was a decrease in the rate of duodenal ulcer in males
from 1952 to 1963 (314,315) while in Copenhagen, during the subsequent six
year period, no significant change was observed (44,45,48). Jonasson
demonstrated that the incidence of new duodenal ulcer cases in Iceland
remained virtually unchanged between 1970 (2.1/1,000) and 1980
(2.0/1,000), although the rate was increasing in females and decreasing
in males (199) .
In the United States, both Fineberg (120) and Smith (352) have
assessed the decline in ulcer surgery. Fineberg went on to assess the
incidence of surgery in the two years following the introduction of
cimetidine and concluded that the decline to a level less than that
predicted was due to the effect of the drug. Mendeloff (264), in his
review, felt that the available data did not permit definite conclusions
and made a plea for improvement in clinical records.
Throughout the rest of the world, values are also available from
Israel (421), Australia (177), including an analysis of data referring to
aborigines (24), Japan (362), India and Ethiopia (248,380). Local
geographic variations in prevalence, with a weighting towards urban
communities, and a gradual fall in incidence over the last 30 - 40 years
are all points which emerged also from the European and North American
studies.
1.1.3 Urban vs Rural
In an attempt to interpret the world literature on ulcer
epidemiology, Susser (371) has stated in his review that duodenal
ulceration is a disease of "early urbanisation" - as the disease
declines in the predominantly white populations of Western Europe and
North America he predicts an increase in previously disadvantaged Third
World populations as they move into the cities. This concept is
supported by data from South Africa (342) and Zimbabwe (123), in that
the diagnosis of duodenal ulcer is being made increasingly frequently in
black Africans who have settled in Salisbury and Harare. This also holds
true in an Australian study (24) which retrospectively found that in the
period before significant urbanisation, there was a striking absence of
duodenal ulcers in the aborigine population.
1.1.4 Summary
In many parts of the world the incidence of new cases of duodenal
ulceration has been falling during the last four decades, long before
the introduction of modern anti-ulcer therapy. On the other hand,
studies of time trends in other defined populations show that the
incidence and prevalence rates have not changed, or have increased, with
clear implications both for our understanding of ulcer aetiology and for
the planning future health resources.
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The "Sword and the Shield" is a concept which has been proposed by
Hunt (181) in discussing both ulcer aetiology and therapy, and is used in
this review as a frame of reference when considering aggressive and
defensive factors in the preservation of mucosal integrity. Despite the
many facets of ulcer disease of which we remain ignorant, such as why
ulcers are focal; why they remit and relapse; and why only some are
painful, it seems that peptic ulcers are still appropriately named
because they depend on the presence of gastric juice. Thus, in patients
with pernicious anaemia who cannot secrete acid or pepsin, ulcers are
extremely rare. In contrast, less than 10% of patients with the
hypersecretory state of Zollinger-Ellison syndrome do not develop
ulcers.
1.2.2 Histamine
There are three major classes of chemical messengers - endocrine,
paracrine and neurocrine - which regulate function within the body, and
all three are important in the regulation of acid secretion (114,146).
This is illustrated in Fig 1.2 I which is adapted from Soil (356).
These three mechanisms together form a group of potential pathways for
the inhibition of gastric secretion:
1. Inhibitors of cell receptors Histamine H2 receptors
Muscarinic receptors
Gastrin receptors
In addition, gastric parietal cells can be inhibited by blocking
intracellular processes involved in acid secretion:
2. Inhibitors of cell activation Prostaglandins E and I
3. Inhibitors of proton pump Substituted benzimidazoles
Two hypotheses have been proposed for the involvement of histamine
in the stimulation of gastric secretion. Firstly, it has been suggested
that histamine, released as paracrine agent, acts as a "final common
pathway" for stimuli acting not only to release histamine directly but
also stimuli acting on cholinergic and gastrin receptors. The latter
were considered somehow to release histamine which, in turn, activated
the histamine receptors of the parietal cell (73). Alternatively, it
was proposed that each parietal cell had receptors for histamine, acetyl
choline and gastrin and that these receptors were functionally
interdependent, so that blockade of one interfered with the efficacy of
the stimulus to the parietal cells provided by the other two (144).
The possibility that histamine was the final common pathway for
paracrine stimulation of the parietal cell was hotly debated for many
years (74,198,75,360), but the observation that H2 antagonists blocked
not only the stimulatory effects of histamine, but also of gastrin and
vagal stimuli, seemed to provide strong evidence that histamine played
an important role in the regulation of all these major pathways
(40,135, 144) .
Histamine is formed by decarboxylation of L-histidine through the
action of the enzyme histidine decarboxylase (HDC). Although a second
(DOPA) decarboxylase exists in mammalian gastric mucosa, this does not
seem to be involved in significant histamine formation in vitro (12).
Histamine degradation is primarily by methylation, through the action of
histamine methyl transferase (HMT) although oxidative deamination of the
side chain also occurs through the action of a group of enzymes called
the diamine oxidases.
In man, the concentration of histamine is greatest in the corpus,
intermediate in the fundus and least in the gastric antrum. At the
cellular level, the distribution of histamine in the rat is highly
correlated with HDC and the cellular fractions with the highest content
of these substances contains 8-12% of a cell population whose electron
microscopic appearances are those of enterochromaffin-like (ECL) cells.
It is estimated that the concentration of histamine within the ECL cells
is about 2-8 pg/cell, which is lower than the 17 pg/cell for the mast
cell population (357) but of a similar order to dog mucosal mast cells
(354). Lorenz has been careful to distinguish, both in human and canine
gastric mucosa, between the atypical and the typical mast cells, since
the former contain 90% of the histamine content of the mucosa. He
concluded that in humans, atypical mast cells within the gastric mucosa
are histamine stores which release histamine and so stimulate the
parietal cell (379). The existence of specific binding sites on the
parietal cell for different gastric stimulants is still in doubt though
Soil (359) has demonstrated binding of gastrin 17 to canine parietal
cells.
Lorenz and co-workers have shown that the gastric mucosal histamine
content of duodenal ulcer patients is less than the levels in controls
subjects (381,382,244,379) and this finding has been confirmed by other
workers (249). Although the evidence in animals is conflicting (330,318)
studies in human volunteers (242) and duodenal ulcer patients (250) have
shown an increase in the output of histamine during pentagastrin
stimulation. Not only has an inverse relationship been demonstrated
between individual peak acid outputs and mucosal histamine
concentrations but a direct relationship has also been demonstrated
between the decrease in peak acid output after vagotomy and the rise in
mucosal histamine (243).
One of the questions which remains unanswered is whether the
differences in mucosal histamine content in patients with duodenal ulcer
is a result of acid hypersecretion or whether mucosal histamine occupies
a primary place in altering secretory status and thus contributes to the
pathogenesis of ulcer disease. This topic has been recently reviewed by
Parsons (291). The role of histamine in the control of gastric
secretion, and the effect on histamine metabolism of H2 receptor
antagonists, is further considered in Ch 6.1.
1.2.3. Acid
The average rate of acid secretion in duodenal ulcer patients is
higher than that in controls, although about two thirds of patients
secrete within the normal range. While patients with gastric ulcer tend
to have decreased acid secretion, most of them secrete within the normal
range. Figure 1.2 II depicts the trends and overlaps in the various
secretory states and is adapted from the monograph by Dr J H Baron (23).
Peptic ulcer results from an imbalance between the acid and pepsin to
which the duodenal mucosa is exposed and the capacity of the mucosa to
resist the damage resulting from that exposure. In addition to noting
the overlap between maximal acid output of normal individuals and
duodenal ulcer patients, Sircus divided ulcer patients into three groups
according to basal and stimulated acid outputs - a) both elevated b)
both normal and c) elevated basal but normal stimulated (350). The
possibility that the higher acid output might be secondary to the
formation of an ulcer has been considered (119) but the evidence from
South Africa to support this has been severely criticised on statistical
grounds (351). There is now some evidence (176) that the concentration of
acid delivered to the duodenum is more important than the total acid
load (the product of concentration and volume) in ulcerogenesis.
Certainly, the regimens of H2 receptor antagonists in current use
suppress concentration to a greater degree than the anticholinergic
drugs which have been used to heal ulcers, and this is consistent with
the higher healing rates obtained with H2 receptor antagonists .
Clarification of the relative importance of acid concentration and
acid load in ulcer healing may also help to clarify the role of acid in
ulcer pathogenesis. Studies which address this issue, however, face a
number of methodological problems in assessing gastric acid secretion,
particularly during 24hr studies. Thus, if one approximates the
physiological situation by normal feeding, total 24 hr aspiration is
impossible but measuring hydrogen ion concentration or pH in aliquots of
gastric contents throughout the day does not permit assessment of acid
output, which is, in part, dependent on the rate of gastric secretion
(volume of gastric juice). A recent paper from the Dallas group (116) has
partially overcome this problem by performing aspiration during
nocturnal and interprandial periods, and intragastric titration during
postprandial periods. In this study, 24hr acid output was almost twice
as high in 8 duodenal ulcer patients as in 7 normals indivduals.
Although cimetidine 400mg twice daily reduced acid output in the ulcer
group to levels not significantly different from controls before
treatment, parietal cell vagotomy reduced acid output by a further 50%.
The authors concluded that the findings of their study support the
concept that both diurnal and nocturnal acid secretion are important in
ulcer pathogenesis, quoting studies (296,186) which rely mainly on diurnal
or nocturnal secretory control yet which both effectively accelerate
ulcer healing. On the other hand, Jones et al (176) have demonstrated a
highly positive correlation between the level of suppression of
nocturnal acid concentration and the healing rates obtained with any
particular drug. It may be that, as the Dallas group have demonstrated,
acid secretion in ulcer patients is increased throughout the 24 hours
but that nocturnal secretion, when acid is not buffered by food, is more
important in ulcerogenesis. Boyd (53) has, however, noted that there was
no discernible relationship between nocturnal acid suppression and ulcer
healing, although the number of patients in the study was too small to
permit a statistically powerful conclusion.
That acid is important in duodenal ulcer disease is evident from
the efficacy of the H2 receptor antagonists in healing ulcers. In the
next two sections the roles of histamine and gastrin in the control of
acid secretion and the pathogenesis of duodenal ulcer disease will be
considered.
1.2.4 Gastrin
Although Edkins (103) was the first to observe that intravenous
injections of extracts of antral mucosa stimulated acid secretion in
animals, naming the active factor gastrin, much criticism and
controversy surrounded this work because the extracts also contained
histamine. Some thirty years later it was shown that histamine free
extracts still caused stimulation of acid secretion (212) but the
controversy continued. It was only with the isolation of pure gastrin
from hog antral mucosa (143) that this controversy finally ended. Since
the successful immuno-assay of gastrin by McGuigan in 1968 (258), the
role of this hormone in gastric secretion and in the pathogenesis of
ulcers has been extensively reviewed (397,398,259).
Although the presence of marked hypergastrinaemia due to the
Zollinger-Ellison syndrome causes duodenal ulceration in more than 90°»
of patients, duodenal ulcer patients have been reported both to show
increased basal and/or postprandial gastrin levels (224,113,77) or to have
values not significantly different from control (non-ulcer) subjects
(259). There remains, however, the possibility of increased gastric
sensitivity to the effects of gastrin, as demonstrated by pentagastrin
infusion in patients with duodenal ulcer (224).
1.2.5 Pepsin
The role of pepsin in the pathogenesis of duodenal ulcers remains
an enigma. There is clear evidence (337) that experimental ulceration of
stomach, duodenum and jejunum is not possible with acid alone, but
requires the presence of pepsin. Increased pepsin secretion in ulcer
disease has been noted (390,376), although an earlier study (179) found
that pepsin secretion was of the same order as in normals. H2 receptor
antagonists have been reported to increase (65,139), leave unchanged
(335) and decrease (241) pepsin secretion. Two reasons for the
discordance in these findings are the variability of biological assays
and the fact that, as peptic activity is pH dependent, changes in
gastric pH effected by H2 receptor blockade will cause changes in peptic
activity (34) .
Two sub-types of the precursor of pepsin, pepsinogens I and II can
be measured in serum. Although this may be of interest on an
epidemiological basis - serum pepsinogen I and II are both elevated in
duodenal ulcer, an elevated serum pepsinogen I was associated with a
threefold higher odds ratio for duodenal than for gastric ulcer and an
elevated serum pepsinogen II was associated with a three fold higher
odds ratio for gastric than for duodenal ulcer (333) - the relationship
between serum pepsinogen and gastric pepsin secretion has not been
established.
1.2.6 Campylobacter Pyloridis
Although the majority of the research which has been undertaken on
aggressive factors in ulcer pathogenesis has been concerned with the
role of acid and pepsin, the concept that bacteria might play a part in
breaching the mucosal barrier has been suggested in recent years as a
result of the finding and study of a campylobacter-like organism (CLO or
C. pyloridis. "Spirochaete organisms" were first reported in the stomach
of the dog almost one hundred years ago (39), and, fifty years later
(79,96) in both monkey and human stomach. After Warren's initial report
in 1983 (403) several groups around the world have examined gastric
mucosal biopsies by culture and microscopy for these organisms
(251,328,201,262,252,227,64,267,309,178,301,253,254). To date, no
convincing evidence has been produced that the organism causes
ulceration, although there does seem to be an association with antral
gastritis.
1.2.7 Herpes simplex
There is a striking similarity between the clinical course of
duodenal ulceration and of aphthous ulceration of the buccal mucosa. The
aetiology of pain in both conditions, which remit and relapse without
demonstrable cause, is poorly understood. Although infection with herpes
simplex causes small vesicles which disappear spontaneously and peptic
ulcer runs a protracted course, often with deep ulceration, Borg (49)
has suggested that these differences may be accounted for by the effect
of acid and pepsin in the duodenal bulb. A study of patients undergoing
vagotomy for peptic ulceration reported that 90% were carriers of herpes
simplex (3). Antibodies to this virus have been found both in serum
(391) and in duodenal fluid (329) in a significantly greater proportion
of patients with active duodenal ulcer than in normal controls.
1.2.8 Prostaglandins
Prostaglandins are ubiquitous hormone-like substances, unstable
with biologically active metabolites, and present in minute amounts in
almost all body tissues. They have been shown to fulfill three roles in
maintaining the integrity of the mucosa of the upper alimentary tract:
1) Inhibition of gastric secretion 2)"Cytoprotection" - prevention of
damage to the sub-epithelial layers of mucosa from agents such as
ethanol and aspirin 3) facilitation of mucosal repair. Malagelada's
group from the Mayo Clinic (2) have demonstrated that prostaglandin
synthesis in the duodenal mucosa is increased in response to a meal in
normals, but not in duodenal ulcer patients. In addition, in animal
studies, it has been shown that perforated ulcers, just distal to the
pyloroduodenal junction developed in 7 of 10 rabbits used for production
of high titre plasma antibody to 6-keto PGF1 alpha and PGE2. The
remaining rabbits developed imperforated ulcers or gross erosions (285).
Interpreting these findings as indicating that prostaglandins have a
protective effect on the gastric and duodenal mucosa may be an
oversimplification, however, as PGE2 inhibits gastric acid secretion
(26) and indomethacin, a prostaglandin synthesis inhibitor, stimulates
acid production (115). Reference has already been made (Ch 1.2.3) to the
study relating the efficacy of ulcer healing compounds to their
antisecretory effects (176). The ability to heal ulcers of some of the
synthetic prostaglandins is exactly as one might predict from their
inhibitory effect. The ulcer healing ability of these compounds may
therefore be related more to acid inhibition than cytoprotection, a
concept which is explored further in Ch 4.
1.2.9 Gastric Mucosal Bloodflow
Focal reductions in gastric mucosal bloodflow, with resultant
ischaemia, have been proposed as a possible explanation for the
restricted area of mucosa involved in gastric and duodenal ulcer disease
(145). The methodology to confirm this hypothesis is currently
inadequate. Clearance techniques (191) and the use of radioactive
microspheres (11) do not permit rapid repitition of measurement or
assessment of focal areas of relative ischaemia, although the latter
technique has been used to show that increases in gastric mucosal
bloodflow during sepsis in an animal model may be prostaglandin-mediated
(282) and that the mucosal ischaemia associated with stress-ulcers may be
reversed by topical PGE2 (129).
Cysteamine, a known ulcerogen, has been reported to cause an
increase in rat gastric mucosal bloodflow when measured by microsphere
(372) but a decrease in the same parameter is detected when measured by
hydrogen clearance (420). Szabo, in his review (373), concludes that
although decreased bloodflow is probably not sufficient to initiate
localised duodenal ulceration, exposure of ischaemic mucosa to
unbuffered acid in the duodenal bulb may induce such lesions.
1.2.10 Mucus and Bicarbonate
Nearly thirty years ago Heatley (163) proposed the concept of a pH
gradient across the gastric mucus barrier. This role of mucus and
bicarbonate secretion as factors in the protection of the gastric mucosa
was reviewed by Allen and Garner (4), who drew particular attention to
the depth of the gel layer, the ability of luminal acid to stimulate the
secretion of bicarbonate and the special resistance of certain cell
membranes, such as those of the gastric glands, which are not covered by
mucus. Prof Allen has also contributed to a study suggesting that the
peptic activity of gastric juice from duodenal ulcer patients is
mucolytic at higher pH than is the juice from non-ulcer control patients
(182). Associated with this is the finding that the thickness of the
mucus layer is significantly less in patients with duodenal ulcer (81).
Fig 1.2 I Endocrine, paracrine and neurocrine control of parietal cell
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2 DESIGN AND METHODOLOGY
2.1 Rationale
From evidence cited in Ch 1.1, it is clear that demands for
pharmacological and surgical intervention remain a significant burden on
the health services. It has been estimated (221) that the cost in lost
wages alone in the United States are between 1.3 and 2.6 billion
dollars.
The types of groups of drugs, and the numbers of drugs of each
type, available for the treatment of duodenal and gastric ulcer have
grown in exponential fashion over the last decade. Although several
burimamide, oxmetidine, metiamide, tiotidine, loxtidine - of the H2
receptor antagonists have been withdrawn, there are even more -
cimetidine, ranitidine, nizatidine, etintidine, famotidine, CM 57755,
ICI 162,846 - which have become established or are in the process of
establishing themselves in the market place. Some of the polycyclic
drugs can claim just as long a lineage in the therapy of duodenal ulcer
(147) and, with the advent of more specific antagonists of the gastric
muscarinic receptors such as pirezepine, prove a viable alternative
choice to the prescriber. The explosion of research into prostaglandins,
especially the synthetic analogues, and the advent of extremely powerful
antisecretory agents such as the substituted benziraidazole omeprazole,
further expand the therapeutic options.
With this background, the traditional place of antacids has been at
least displaced, if not dislodged. After it was proved (296) that
antacids given in high dosage did actually accelerate the healing rate
of duodenal ulcers, the subsequent tendency has been to progressively
reduce the amount of antacid used (223,35,220) in attempts to establish
the minimum effective dosage, especially because high doses of the
magnesium-containing compounds cause diarrhoea.
The following studies examine examples of many of the above types
of anti-ulcer drugs, both in the laboratory in healthy volunteers and by
monitoring the response in duodenal ulcer healing trials. The results of
these studies form the basis of a discussion of current options in the
therapy of duodenal ulcer.
2.2 Project Design
The basis of the thesis involves studies which cover a time-span of
six years. Preliminary data from animal studies, such as in the section
on prostaglandins, are presented before the data generated by studies in
healthy volunteers. These clinical pharmacological investigations
precede the results of clinical trials - acute healing, refractory ulcer
healing and maintenance therapy. Studies involving compounds which have
less of an effect on intragastric pH, such as the antacids, or a weaker
anti-secretory effect, such as the polycylic drugs and prostaglandins,
are presented before the more powerful anti-secretory agents such as the
H2 receptor antagonists and omeprazole.
Several of the ulcer healing studies, of both acute and refractory
ulcers, formed part of multicentre studies and the main authors are
acknowledged at the beginning of the thesis. Where results from other
centres are included for analysis, these are derived from a protocol
identical to that described in the methodology.
All of the secretory studies, with the exception of the antacid
study, were performed in Ninewells hospital. The methodology for the
antacid study however, which was undertaken at McMaster University,
closely followed that which had been followed in Dundee.
2.3 Methodology
All subjects and patients underwent detailed screening involving
questionnaire, clinical examination, urinalysis, ECG and both
biochemical and haematological profile - before entry to the studies.
The haematology (FBC, platelets, red cell indices, white cell
differential, film and ESR), the biochemistry (Urea, electrolytes,
glucose, calcium, phosphate, urate, protein, albumin, bilirubin,
alkaline phosphatase, AST and GGT) and the urinalysis were repeated on
completion of the study. No other medication was permitted in the
healthy volunteers and any anti-secretory medication taken by patients
was discontinued 48 hrs before the study.
2.3.1 Nocturnal Gastric Secretion
Subjects were requested to refrain from the consumption of alcohol,
caffeine-containing beverages and cigarettes for 24 hours before entry.
After a light evening meal (scrambled egg, mashed potatoes, jelly and
ice cream) at 1800 hrs, a 12 FG vented nasogastric tube (Argyle
Catheters) was passed into the stomach at 1945 hrs. Optimal position of
the tube was then confirmed by the water recovery test (159) and the
gastric contents were aspirated and discarded. Continuous low pressure
aspiration was then applied by means of a suction pump and gastric
contents were collected in a glass measuring cylinder. The volume
collected at the end of each hour was recorded and an aliquot (5-10 mis)
stored at 4 degrees Centigrade for analysis of pH, acid concentration
and peptic activity within 12 hrs of completion of the test.
The pH and acid concentration were determined by automatic pH meter
(Radiometer Copenhagen) which titrated to pH 7.0 with 0.1N sodium
hydroxide. Peptic activity was assessed using the method described by
Berstad (31). The output of acid and pepsin were calculated in mmol and
mg per hour or 12 hours, as products of the volume/1,000 and the
concentration of acid (mmol/1) and pepsin (mg/1) respectively.
2.3.2 Pentagastrin-stimulated secretion
Following an overnight fast, a nasogastric tube was positioned as
above, gastric contents discarded and continuous low pressure suction
applied. After one hour (basal), pentagastrin was administered by
continuous intravenous infusion at 0.6mcg/kg/hr. Gastric contents were
aspirated, measured and analysed as before. A modified duodenal tube
manufactured from radio-opaque polyvinyl tubing was passed at the start
of the procedure when medication was to be administered enterally (Fig
2.3 I). Thus it was possible to test the effect of a compound on
pentagastrin-stimulated secretion without interrupting gastric
aspiration after administration of the drug. The presence of bile-
stained alkaline aspirate was taken as evidence that the tip of the tube
lay distal to the pylorus and, following administration of the drug, an
infusion of phenol red was commenced through the duodenal tube.
Significant pyloric reflux of duodenal contents could thus be detected
and, in that event, the study was abandoned and repeated on another day.
After one hour, either the drug or placebo was administered through the
duodenal tube on different days in random order and aspiration continued
for a further one or two hours.
2.3.3 24 hour Secretory Tests
These were carried out from 2000 hrs to 2000hrs (Dundee) or 0700hrs
to 0700 hrs (McMaster). Total gastric aspiration was performed in Dundee
from 2000 hrs to 0800 hrs. Then, with the nasogastric tube left in situ,
the volunteers ate three standardised meals at 0800, 1200 and 1800 hrs.
Aliquots of 5 mis were withdrawn hourly for estimate of H+ concentration
and peptic activity.
2.3.4 Endoscopic examination
All patients attended for endoscopy at 0900 hrs, following an
overnight fast. After informed consent, premedication was given with up
to 20mg of diazepam intravenously and examination carried out to the
second part of the duodenum with the Olympus P2 forward-viewing
gastroscope. Biopsies, when taken, were obtained with the P2 forceps,
which were also used to gauge the size in mm of ulcer craters.










3.1 Introduction and Pharmacology
Antacids are the most time-honoured of all therapies which are
still in current use for dyspeptic disorders. Pliny in the first century
AD and Paracelsus in the sixteenth century recommended the use of
crushed coral and pearls respectively (395). The rational basis for the
use of antacids in the therapy of duodenal ulcer is either for the
relief of pain - the mechanism is not clearly understood but may be
related to changes intragastric pH (414) - or in the belief that
antacids actually alter the natural history of the disease if sufficient
antacid is given to neutralise gastric acid and abolish peptic activity.
Both of these viewpoints are considered in a review by Lambert (225) on
the use of antacids in duodenal ulcer disease. The study by Peterson
(296) was the first to demonstrate acceleration of healing of duodenal
ulcer with antacids under randomised double blind conditions. Not only
has the efficacy of antacids in affording relief from symptoms been
questioned (370) but the dose of antacid in terms of mEq of buffering
capacity which is required to accelerate the healing rate of duodenal
ulcer has also been a topic of some controversy. This topic has been
reviewed in editorials both by Langman (230) and Heading (162) , with
particular emphasis on the optimal dose of antacid required. Several
authors have demonstrated a significant advantage over placebo in the
healing of ulcers with relatively low doses of antacid (223,35,220) in
regimens which would clearly still permit considerable continuing
intragastric peptic activity.
The publication of a fourth study (405) demonstrating the efficacy
of low dose antacids in duodenal ulcer disease prompted the following
study to be undertaken, seeking to establish a rational basis for these
findings in terms of intragastric acidity .
The antacid tablets used were Link 1100 (identical to those in the
Weberg study) which consisted of aluminium hydroxide and magnesium
carbonate in a co-dried gel. Each tablet had an acid buffering capacity
of 30 mmol. The placebo tablets consisted of mannitol and sorbitol, with
negligible buffering capacity.
3.2 Subjects and Modifications to Methods
The subjects were seven healthy young male non-smokers, aged from
20 to 25 years (mean 24 years). Meals were identical in timing and
content on both days and, as in the Weberg study, tablets were
administerd in double blind fashion four times daily - 1 hour after
meals and at bedtime. The procedure for passing and positioning the
nasogastric tube was as described in Ch 2.3. The pH of the gastric
aspirate was determined hourly. Individual glass electrodes were used
for each subject thus avoiding the risk of cross infection when the
aspirate was returned to the stomach. The concentration of acid was
calculated from the pH (1/antilog pH x 1000) and statistical analysis
undertaken by ANOVA.
3.3 Results
Mean pH and H+ concentration on control and active therapy are
shown in Tables 3.3 I and II. These results are also depicted
graphically in Figs 3.3 I to IV. For purposes of analysis, each 24 hour
period is broken into morning (0700-1200 hrs), afternoon (1300-1800
hrs), evening (1900-2300 hrs) and night (2400-0700 hrs). During
administration of antacids there is a significant decrease in acid
concentration in all time periods except during the night, with the
greatest of the decreases in the morning, although the highest value of
significance was in the evening.
Table 3.31 pH of gastric aspirate



































































Fig 3.3 I Effect of antacid on gastric acidity (mean hourly pFI)
EFFECT OF ANTACID ON GASTRIC ACIDITY
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Fig 3.3 II Effect of antacid on gastric acidity (mean period pH)
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Fig 3.3 III Effect of antacid on gastric acidity (mean hourly H+)
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Fig 3.3 IV Effect of antacid on gastric acidity (mean period H+)
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3.4 Discussion
The absence of apparent effect of one 30 mmol buffering capacity
antacid tablet on nocturnal intragastric pH was less surprising than
the extent of the effect of these tablets when administered post-
prandially. There was a significant fall in intragastric acidity
following all three meals on the active therapy day. Despite the
widespread availability and use of antacids, a number of side effects
have been described - hypercalcaemia, binding of other drugs,
stimulation of gastrin release, binding of phosphate with resultant
osteomalacia, copper deficiency and aluminium toxicity which has been
linked to Alzheimer's disease (165,8,80), although the latter is not
proven (204). Not only is it important to establish the minimal
effective dosage of antacid to diminish side effects, but also to reduce
cost and increase compliance. Although a number of mechanisms have been
invoked other than a reduction in intragastric acidity to explain ulcer
healing with antacids, such as binding of pepsin, bile acids and
lysolecithin (34,27), and direct cytoprotection (151,374), the reduction
in meal stimulated acid demonstrated in this study may account for the




4.1.1 Synthesis and Biochemistry
Prostaglandins are derivatives of 20-carbon-chain unsaturated fatty
acids and, as such, form part of a larger group of biological agents
called the eicosanoids, together with leukotrienes, thromboxanes and
lipoxins (121,160,272,343). The synthetic pathway is illustrated in Fig
4.1 I. The carbon atoms are numbered starting with the carboxyl radical,
the letter (A through J) denotes changes in the ring structure and the
number (1 through 3) refers to the number of double bonds in the side
chains.
Prostaglandins E, F and I are present in the gastric mucosa and
gastric juice, and both the synthetic and degradative enzymes of
prostaglandin metabolism are present in gastric epithelium. A major
stimulus to the synthesis of prostaglandins is trauma, whether
mechanical or chemical (37,29,209,87,215,216,323,324). There is,
consequently, an immediately apparent problem in assessing the
significance of mucosal "content" of prostaglandins since this may
merely be a reflection of synthesis stimulated by the process of taking
the sample. In addition, the half-life of naturally occurring
prostaglandins varies from a few seconds to several minutes (325).
Lastly, both platelets and leucocytes are potent sources of
prostaglandins. Contamination with blood and minor variations in the
methodology may therefore give rise to the major differences in the
levels of prostaglandins within gastric and duodenal tissue reported in
different studies.
4.1.2 Mucosal prostaglandins and ulcer pathogenesis
In laboratory animals (rabbits) in which antibodies to PGE2 and 6-
keto PGF1 alpha were developed, an extremely high incidence of
aggressive duodenal ulcer disease was noted (285). The concept that
these results might be due to an abnormally low level of tissue
prostaglandins was therefore developed, but has lost ground with the
finding that, in humans, there is no evidence in the duodenal ulcer
population that specific serum binding to these prostaglandins exists
(319) .
There have been conflicting reports on the levels of prostaglandins
in patients with ulceration or inflammation of the upper
gastrointestinal tract. Over the last decade, there have been four
reports demonstrating no change (214,5,2,210), six reports of a decrease
(347,169,217,312,313,418)and three reports (161,71,338) of an increase
in prostaglandin synthesis or content. Synthesis of PGE2, PGD2, TxB2,
PGF2 and PGF1 alpha was reported to be similar in a group of controls to
that in patients with active duodenal ulcer in the fasting state but, on
feeding, synthesis increased in 5 out of 8 normals, but decreased in 8
out of 10 duodenal ulcer patients, after feeding (2). Thus, there may be
primary abnormalities either in the synthesis or in the release of
mucosal prostaglandins in ulcer disease but in order for progress to be
made, a considerable number of methodological problems have to be
overcome.
The first study, therefore, examines the relationship between
"content" and "synthesis" of two prostaglandins (E2 and 6-keto F1 alpha)
in biopsies of rat gastric corpus mucosa. In addition, since this
problem had not previously been addressed, the effect of different sizes
of biopsy forceps on these parameters was also assessed.
4.1.3 Exogenous prostaglandins and gastric secretion
Many of the naturally occurring prostaglandins of the E and I
groups lower cyclic AMP in parietal cells (356) and inhibit gastric acid
secretion (322,406). Oral PGE2 may or may not be an antisecretory agent
in humans (203,211,321). The addition of a methyl group, however,
reduces the rate of degradation and both Trimoprostil and Enprostil are
capable of inhibiting basal, meal-stimulated and pentagastrin/histamine-
stimulated gastric acid secretion (409,88,89,247). The combination of
this anti-secretory action and the ability of prostaglandins to protect
the sub-epithelial layers of the duodenal mucosa from damage by
injurious agents such as ethanol (322) make this group of compounds
theoretically very attractive in the therapy of peptic ulcer disease.
With these findings in mind, it was felt to be particularly relevant to
examine the anti-secretory ability of two of the synthetic
prostaglandins, trimoprostil and enprostil, in healthy volunteers with
particular reference to nocturnal secretion.
Table 4.1 I enumerates the healing rates obtained in endoscopically
controlled double-blind trials with the synthetic prostaglandins which
have been published to date. Hunt and his colleagues have analysed the
healing rates of duodenal ulcer obtained with a number of compounds,
including some of the synthetic prostaglandins and compared these with
the ability of the compounds to inhibit the concentration of nocturnal
acid (176). Not only is there a direct linear relationship between these
two parameters but the same relationship exists for the synthetic
prostaglandins. This suggests that the ability of the synthetic
prostaglandins to accelerate ulcer healing is related purely to the acid
inhibitory component rather than to any "cytoprotective" effect.




PGD2 PGF2 PGE2 Prostacyclin Thromboxane
HETE = hydroxyeicosatetraenic acids
Table 4.1 I Four week healing rates of duodenal
ulcer with prostaglandins
Drug Dose No of Trials No of patients % healed
Enprostil 70mcg bd 2 47 80.9
Enprostil 35mcg bd 2 252 72.2
Misoprostol 200mcg qid 2 181 69.6
Arbaprostil 100mcg qid 1 82 67.0
Trimoprostil 750mcg qid 1 30 61.0
Misoprostol 50mcg qid 2 173 43.9
References (10,58,22,234,281,57,21,389)
4.2 Mucosal Prostaglandin Content
4.2.1 Methods
All gastric mucosal samples were obtained from male Wistar rats,
fasted for 24 hours and anaethetised by pentobarbital given
intraperitoneally. A gast.rotomy was performed, the gastric mucosa
flushed gently with normal saline and three serial sets of biopsies were
obtained from contiguous areas of gastric corpus with the Olympus P2 and
IT forceps. Total thickness (TT) samples of the stomach were also
obtained by excision biopsy.
Each set of three samples were then placed individually in three
wells containing 1ml of Hanks plus 0.35% bovine albumin (HBSS). To one
of the three wells was added 100 microl of BTG (an anticoagulant that
blocks prostaglandin synthesis). The biopsies were transferred after ten
minutes to a second set of wells, one of which contained arachidonic
acid (AA), which stimulates prostaglandin synthesis. After a further ten
minutes, all biopsies were transferred to a third set of wells, and
prostaglandin synthesis blocked by BTG in the remaining two wells (see
Fig 4.2 I) .
Aliquots of the supernatant were then frozen and stored at -70
Centigrade. Assays were carried out in single batches by radio¬
immunoassay for PGE2 and 6-keto PGF1alpha. In order to test whether any
differences observed were dependent solely on the sample size or whether
the thickness of the biopsy influenced the results independently of the
total weight of the biopsy (different levels of prostaglandin content
might be present at different levels in the mucosa), multiple mucosal
samples were taken with each biopsy technique and weighed.
Results are tabulated as shown in Tables 4.2 I, II and III and
analysis undertaken by 3-way ANOVA.
4.2.2 Results
Both the variations of biopsy size (p=0.0014) and level of
stimulation (p=0.0001) have a highly significant effect on prostaglandin
levels. The effect of the interaction of the two variants, however,
fails to reach the level of conventional significance (p=0.0636).
If an adjustment is made according to biopsy weights from Table 4.2
III a different picture emerges (Table 4.2 IV). It can be seen that, in
pg/ml/mg, stimulated (AA) levels of PGE2 and 6-keto PGF1 alpha increased
to the highest level for both prostaglandins in the more superficial
(P2) biopsies.
Fig 4.2 I Methodology and sequence of biopsy preparation
1. o o o
10 minutes HBSS+BTG HBSS+BTG HBSS+BTG
2. o o o
10 minutes nil nil nil
3. o o o
Table 4.2. I 6-keto PGF1 alpha (pg/ml)
P2 IT TT
BTG HBSS AA BTG HBSS AA BTG HBSS AA
1 . 1600 5970 8920 3130 5420 6610 5250 10300 8920
2. 2180 1510 6580 2480 1560 5940 8770 10260 8920
3. 1100 3000 2680 680 1480 2010 1320 4120 7320
4. 1320 700 420 3280 5560 2040 2000 7360 2280
5. 2180 4910 8590 830 6780 7740 4440 6330 8680
6. 860 2240 5920 4820 6340 8140 4410 3510 8920
7. 530 4040 7770 400 10320 12410 10690 6890 13770
8. 540 2080 7740 880 3770 6810 2000 2170 8620
9. 770 960 6420 410 1880 15110 1640 3480 6610
10 180 525 4560 200 1310 3460 260 380 3490
SD 689 1815 2711 1597 2976 4219 3401 3317 3189
X 1210 2240 6500 855 4595 6710 3205 5225 8650
Ra 180- 960- 420- 200- 1310- 2010- 260- 380- 2280-
2180 5970 8920 4820 10320 15110 10690 10300 13770
Table 4. 2 II PGE2 pg/ml
1 901 282 7072 1849 267 7842 2307 4040 8162
2 1064 135 9665 1450 304 8694 3340 1474 10265
3 226 1468 558 162 1161 994 2021 3821 3752
4 697 133 569 4682 3228 2055 2536 6486 1269
5 335 1517 11439 510 2355 16948 1007 1588 15669
6 254 83 8870 1197 2351 12715 1728 1501 15100
7 503 992 9029 735 2809 18042 4756 2384 20183
8 206 668 10621 846 1355 13507 2181 1656 16365
9 25 128 5112 35 202 7962 393 448 4219
10 88 42 6533 636 1152 11499 563 753 13003
SD 352 579 3861 1367 1108 5673 1310 1850 6299
X 430 555 6947 1030 1518 10023 2083 2415 10799
Ra 25- 42- 558- 35- 202- 994- 393- 448- 1269
1064 1468 11439 1849 2809 18042 4756 6486 20183
Results are given for each individual animal 1-10, for each biopsy size
(P2, IT and TT), at each level of stimulus (BTG, HBSS and AA) with Mean
(x), Standard Deviation (SD) and Range (Ra).















Median 9.1 12.7 4.2
Mean 10.4 11.9 4.0


























4.3.1 Introduction and Pharmacology
Trimoprostil (11R,16,16-trimethyl-11-desoxy prostaglandin E2) is a
PGE2 analogue (Fig 4.3 I) which, in studies on inhibition of basal
gastric secretion in the rat, has been reported to be approximately
2,000 times more potent than cimetidine on a molar basis (124). Further
animal experiments have shown that it is effective in preventing
duodenal ulcers caused by pyloric ligation, stress or indomethacin
(124). Approximately half of an oral dose is absorbed from the stomach
and the drug is almost totally excreted in bile. Maximum plasma
concentration is achieved in 45 mins, but this is delayed to 130 minutes
if administered after food (407). In studies of healthy volunteers, the
IC50 of circulating trimoprostil for basal acid secretion was 1.25
ng/ml, and 70-80% inhibition was achieved with serum concentrations of
3-4 ng/ml (407). Up to 60% reduction of meal-stimulated acid output was
obtained in duodenal ulcer patients with evidence of a dose-response
(237). In order to further define the anti-secretory effects of the
drug, the inhibitory activity of two doses of trimoprostil on 12 hour
nocturnal secretion of acid and pepsin has been compared with placebo in
healthy volunteers.
4.3.2 Modifications to Methods
The studies were performed in eleven healthy male volunteers
(students and laboratory staff) who all had acid outputs of greater than
40mmol/12 hrs, with at least five days between tests. Identical capsules
containing trimoprostil (1.5 or 3.0mg) or placebo were administered
under supervision at 1800hrs with a standardised light evening meal.
4.3.3 Results
Overnight secretion of acid was reduced from 106mmol to 68.4mmol by
trimoprostil 1.5mg and to 49.4 by 3.0mg trimoprostil. Both decreases
were highly significant (p < 0.01) and the inhibition by the two doses
of the drug were significantly different (p < 0.02) from each other (Fig
4.3. II). On an hourly basis, the inhibition of acid secretion by 1.5mg
was significant until midnight, and from 0100-0200hrs (p < 0.01), while
the decrease with 3mg was significant (p < 0.01) until 0100hrs and
remained significant (p < 0.05) until 0300hrs. When expressed as a
percentage of the placebo value (Fig 4.3 III), the reduction in acid
output was greater than 50% until 0200 hrs, after treatment with
trimoprostil 3mg.
The reduction in nocturnal output of acid was mainly attributable
to a decrease in the secreted volume of gastric juice (Fig 4.3. IV)
since a significant reduction in acid concentration (Fig 4.3. IV) only
occurred from 2100 to 2300 hrs with 1.5mg and from 2000 to 0100 hrs with
3.0mg (p < 0.05). The changes in pH were not large and in only one
individual did trimoprostil increase the pH values to greater than 2
during the night (Fig 4.3. VI).
Nocturnal secretion of pepsin was significantly reduced (p < 0.01)
from 2000 to 2200 hrs after 1.5mg trimoprostil and from 2000 to 0100 hrs
after 3.0mg (Fig 4.3. VII). The nocturnal pepsin output after 3.0mg was
significantly less than placebo (p < 0.05).
Fig 4.3 I Structure of trimoprostil
o
11-Methyl, 16, 16 Dimethyl PGE2
(Roche, RO 21-6937, Trimoprostil)
Fig 4.3 II Median acid output on trimoprostil/placebo
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4.4 Enprostil
4.4.1 Introduction and Pharmacology
Enprostil is a synthetic dehydro prostaglandin E2 derivative with a
molecular weight of 400.45 and structure as shown in Fig 4.41. In the
rat model, enprostil at doses of below 7.5 micro g/kg inhibited acid
secretion during histamine stimulation and was approximately 300 times
more potent than the naturally occurring PGE2. From isotopically
labelled studies in man (345), the drug and related major metabolites
have a plasma half-life of 1.75 hours. Approximately 55% is recovered in
urine, the remainder being excreted in the faeces.
The purpose of this study was to examine the effect of enprostil on
nocturnal secretion and to compare this with ranitidine in a group of
healthy volunteers, in order to assess the potential for the treatment
of ulcer disease.
4.4.2 Modifications to Methods
Eleven healthy male volunteers, age 22 (18 - 25) yrs (mean and
range), underwent four separate 12 hour overnight gastric secretory
studies from 2000 to 0800 hrs. Only subjects with an overnight acid
output of > 30mmol and < 80mmolwere recruited. Subjects were randomised
into the following treatment groups according to a Latin square pattern:
1. two capsules placebo, one tablet placebo x2
2. one capsule placebo, one capsule enprostil 35mcg and one tablet
placebo x2
3. two capsules enprostil 35mcg, one tablet placebo (evening)
two capsules placebo, one tablet placebo (morning)
4. two capsules placebo, one tablet ranitidine 150mg x2
Each treatment was taken twice daily. Thus, the four treatments
consisted of placebo, ranitidine 150mg bd, enprostil 35mcg
enprostil 70racg nocte. Each treatment was taken for one week,




Volume, acid output and pepsin output are shown in Table 4.4. I
and II and are illustrated graphically in Figs 4.4. II and III. The
entire data set has been analysed. The only significant change is
reduced acid output with ranitidine (p < 0.05). The data have also been
analysed following exclusion of subjects 2 and 4 (Table 4.4 II) since,
according to the initial entry criteria, they should not have been
included because their nocturnal acid output wa too low. Although, on
repeat analysis, statistically significant change at the 5% level does
not occur with any criterion other than with acid output on ranitidine,
a decrease of 28% in acid output occurs following enprostil 35mcg bd and
of 21% following enprostil 70mcg nocte. Pepsin output was not altered by
any of the drug regimens. The rate of secretion was reduced by
ranitidine by 40% and by about 20% with both dosage schedules of
enprostil.
Table 4.4. I Individual nocturnal outputs - acid, pepsin and volume
Subject Drug Acid (mmol) Pepsin (meg) Volume(mls)
1 P 47. 1 195 1962
R 10.2 102 169
E35 9.3 95 680
E70 28.2 448 878
2 P 12.1 403 782
R 4.6 62 446
E35 5.7 139 586
E70 37.0 599 950
3 P 29.8 684 964
R 5.1 224 854
E35 10.7 322 706
E70 36. 1 671 970
4 P 101 .1 1902 1148
R 15.8 430 610
E35 74.6 1255 974
E70 152.8 1794 1430
5 P 30.7 291 542
R 25.5 253 526
E35 30.2 476 752
E70 34.6 332 552
6 P 59.2 922 836
R 27.9 1164 702
E35 11.5 986 510
E70 40. 1 712 770
7 P 39.0 843 1100
R 34.4 817 644
E35 50.9 1052 860
E70 36.8 579 628
8 P 39.9 479 730
R 16.6 404 496
E35 53.8 514 748
E70 29.0 288 456
9 P 36.6 519 614
R 22.5 778 489
E35 37.6 976 876
E70 27.8 482 548
10 P 69. 1 708 780
R 25.4 704 510
E35 40.3 536 502
E70 61.0 573 770
11 P 73.5 790 1006
R 31.4 805 680
E35 59.5 991 1094
E70 43.7 686 950
Table 4.4 II Mean nocturnal output
Acid (mmol) Pepsin (meg) Volume (ml)
Mean P 48.9 703 951
R 19.9 (59) 522 (26) 564 (41)
E35 35.0 (28) 667 ( 5) 753 (21)
E70 47.9 ( 2) 651 ( 7) 809 (15)
Excl. Subjects 2 and 4
Mean P 47.3 603 948
R 22.1 (53) 583 (3) 563 (40)
E35 33.9 (28) 660 (+9) 747 (21)
E70 37.5 (21) 530 (12) 724 (24)
% change in parentheses





Fig 4.4 II Output of acid (mmol), volume (mis) and pepsin (mg) on
enprostil/ranitidine/placebo excl. subj 2 and 4
flc I d (
SUBJECTS (excluding 2 end 4) NOCTURNAL OUTPUT
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Fig 4.4 III Output of acid (mmol), volume (mis) and pepsin (mg) on
enprostil/ranitidine/placebo subj 1-11
flcld (mmols)
SUBJECTS 1-11 NOCTURNAL OUTPUT
Pepsin (meg) Volume (ml«0
II
Pre Post Pre Post Pre Po s
48.9 19.9 703 522 951 564
48.9 35. 0 703 667 951 753





4.5.1 Mucosal prostaglandin content
Radioimmunoassay is a sensitive, reproducible and widely-used
technique with which, however, it is difficult to allow for biologically
active metabolites. Considering the rapidity and ubiquity of the
prostaglandin cascade, this is a major disadvantage. Within this
limitation, the initial part of this study has demonstrated
statistically significant differences not only between the different
levels of activity (BTG/HBSS/AA) but also between different biopsy
sizes. Care must therefore be taken when comparisons are made between
the results of different groups of workers. One cannot assume that,
simply because results are expressed per mg wet tissue weight, that the
effect of different biopsy sizes is compensated for - clearly the level
to which the tissue is biopsied is just as important as the size of
biopsy. It is therefore recommended that comparisons only be drawn
between mucosal prostaglandin levels from different studies if the level
of stimulation of prostaglandin synthesis, the assay technique and the
biopsy technique are all identical.
Although a wide range in the values was observed, the potential
contribution by this scatter throughout the ten animals to the apparent
differences observed was tested as part of the 3 way ANOVA, but was
found not to contribute to the level of significance obtained.
4.5.2 Trimoprostil
The second study, with trimoprostil, shows that this compound is a
moderate inhibitor of gastric secretion of acid and pepsin at doses of
1.5 and 3.0mg in healthy volunteers whose acid outputs are within the
range that one might expect to find in patients with duodenal ulcer. In
a dose of 0.75mg four times daily in duodenal ulcer patients, a four
week healing rate of 62% has been achieved (21). It seems likely that
the gastric inhibitory effects of trimoprostil account for the ulcer-
healing action of the drug. Diarrhoea has been a troublesome, dose-
related side effect with some of the other prostaglandin analogues. No
side effects were noted by the volunteers in this study, although single
dosing might be insufficient to detect this symptom.
Any advantage which this group of compounds might present over
currently available anti-ulcer therapy seems more likely to lie in the
area of ulcer prophylaxis of sub groups in the population who are at
risk e.g. the elderly taking non-steroidal anti-inflammatories drugs, or
in the maintenance of ulcer remission.
4.5.3 Enprostil
The findings in the third study are in accord with Pounder,s
study on enprostil (334). Nine patients with duodenal ulcer, in
remission, were studied on three occasions - before, and on the seventh
day of therapy with enprostil 35mcg bd and enprostil 70mcg nocte. Twenty
four hour and nocturnal intragastric acidity was reduced by both
regimens by 28% and 28% respectively . In this study also, medication
was well tolerated except by one patient, who developed self-limiting
diarrhoea. The Haslar group (91) also examined a group of nine duodenal
ulcer patients after pre-dosing for two days with enprostil 35mcg bd and
70mcg nocte. Twenty four hour intragastric acidity was reduced by 39%
and 33% respectively, and nocturnal acidity by 60% and 67%. Conceivably,
if the trophic action of enprostil does counteract the anti-secretory
effects, then two days of pre-dosing may be insufficient for this
trophic action to occur. In the study carried out by Pounder and in the
Haslar study the evening medication was given later - 2215 and 2300 hrs
- and this may account for the increase in the degree of nocturnal
suppression in the Haslar study.
As one might expect from the relatively weak anti-secretory
activity of this compound, duodenal ulcer healing studies have been
disappointing. Bardhan (22) found that enprostil 35mcg bd healed only
46% of duodenal ulcers in four weeks, compared with 93% given ranitidine
(p < 0.01). In gastric ulcer, however, efficacy seems to be comparable
with H2 receptor blockade. Using a higher dose of 70mcg bd, Morgan et al
(275) found that, of 48 patients with gastric ulcer randomised to either
ranitidine (R) 150mg bd or enprostil (E), after one month 63% (E) and
50% (R) had healed, after two months 91% (E) and 83% (R) and after three
months 96% (R). No significant difference was found between the two
groups. No anti-secretory data are available using 70mcg bd but, since
70mcg at night did not result in greater nocturnal inhibition than
35mcg, it seems likely that the relatively greater efficacy of enprostil
in gastric ulcer is due to some mechanism other than an increased anti¬
secretory effect.
5 POLYCYCLIC DRUGS
5.1 Mianserin, Trimipramine and Quisultidine
5.1.1 Introduction and Pharmacology
The molecular structures of these three compounds are shown in Fig
5.1 I. Quisultidine, which has not been marketed in the UK, is absorbed
orally with a peak plasma concentration time after dosing of 1.6 hrs
(1.0-2.5 hrs). The elimination half life is variable (1.75-20.0 hours)
with a mean of 7.7 hours (385). Mianserin is readily absorbed from the
gastrointestinal tract and 70% is excreted by first pass metabolism in
the liver through hydroxylation, N-oxidation and N-demethylation. The
plasma concentration curve is biphasic and maximal concentration is
achieved 2 hrs post dose. Mianserin is excreted almost exclusively as
metabolites in the urine, and has an elimination half life of between
7.7 and 19.2 hrs (257). There is some evidence that this may be
significantly prolonged in the elderly (346). Trimipramine is readily
absorbed following oral dosing (as trimipramine maleate), is extensively
plasma bound and is excreted mainly in the urine (88). Following
intravenous administration, the elimination half life is approximately
23 hours (1). Twice daily dosage would therefore be quite feasible
without marked fluctuations in plasma levels.
In 1976 Guldahl (147) reported that many patients with duodenal
ulcer suffered from mild depression. When trimipramine was used to treat
this depression, it was noted that the rate of ulcer healing increased.
Subsequently, it was shown that trimipramine increased the rate of
healing of both duodenal (268,25,246,388) and gastric (388,386) ulcers,
and that continued treatment induced sustained remission in many
patients with ulcer disease (387). Additional studies (327,279) showed
that trimipramine inhibited gastric secretion, an effect considered
relevant to the therapeutic efficacy of the drug.
Boyd and Wormsley (50) demonstrated that the new polycyclic
quisultidine (LM 24056) was a powerful inhibitor of gastric secretion,
so that it seemed relevant to compare the effects of three different
polycyclic drugs on gastric secretion to determine whether gastric
inhibition was a consistent property of this type of compound. As it was
found that mianserin was a gastric secretory inhibitor, eight patients
were entered into an open, pilot, ulcer-healing study.
The only polycyclic drug in common current use in the treatment of
duodenal ulcer disease is pirenzepine. A review was therefore undertaken
of the actions, side effects and efficacy of pirenzepine in duodenal
ulcer therapy.
5.1.2 Subjects and Modifications to Methods
Overnight and pentagastrin-stimulated gastric secretion of healthy
male volunteers (18-30 years) was studied. With quisultidine, a variable
dose study of overnight gastric secretion was also performed in patients
with duodenal ulcer. Subject numbers and dosage schedules are detailed
in Table 5.1. I.
After collection of basal secretion for 30mins, an intravenous
infusion was commenced with pentagastrin 2mcg/kg/hr. After one hour,
either the drug (crushed and dissolved in 20mls saline) or placebo
(20mls saline) was administered through the duodenal tube on different
days in random order and aspiration continued for a further hour. The
methodology for the overnight studies, measurement of acid and pepsin
and statistical analysis were unchanged from previous studies.
5.1.3 Results
The secretion of acid in response to pentagastrin was inhibited by
all three drugs in the doses used in this study (Table 5.1 II). The
output of pepsin was inhibited by mianserin and quisultidine but
increased by 12% after administration of trimipramine.
Overnight secretion of both acid and pepsin was inhibited by
mianserin and quisultidine, but the output of both these components
increased after trimipramine (Table 5.1 III). No significant adverse
reactions were noted during the study. After quisultidine 300mg, most of
the subjects experienced dryness of the mouth. Compared with control
nights, some of the individuals slept better after mianserin and were
more drowsy on the morning following the test.
Endoscopy revealed that seven of the eight duodenal ulcer had
healed patients after administration of mianserin 60mg at night for four
weeks.
Table 5.1 I Subject numbers and Dosage Schedules
Drug Overnight Secretion Pentagastrin Study Dose
(no. of subjects) (no. of subjects) mg
Trimipramine 7 6 50
Mianserin 9 7 60
Quisultidine 5 5 200
Quisultidine (d.u.) 23 100
200
300






















































Control Drug Change p
541+94 583+47 + 8% ns
640+70 368+52 -43% <0.05
703+74 624±121 -11% ns
752+95 380+107 -49% <0.01
785+117 220+83 -72% <0.01
I Structure of mianserin, trimipramine and quisultidine
5.2 Pirenzepine
5.2.1 Pharmacology
Pirenzepine is an antimuscarinic compound which, in adequate
dosage, accelerates the healing rate of duodenal ulcers in man. Combined
four and six week healing rates with 100mg and 150mg are 67% and 76%
respectively, but the corresponding rate for doses of less than 100mg is
58%, suggesting a dose-response relationship. After one year of
maintenance therapy approximately 70% of ulcers remain in remission.
These results are not significantly different from those achieved with
H2 receptor antagonists. The incidence of side effects also appears to
be dose-related - at doses of 100mg and 150mg daily, 14% of patients
admitted to dry mouth. The combination of pirenzepine and cimetidine has
potent anti-secretory and ulcer-healing effects. The most effective
roles for this compound are in healing refractory ulcers (in combination
with an H2 receptor antagonist) and in maintaining ulcer remission.
The polycyclic compound pirenzepine is a pyrido-benzodiazepine
(Fig 5.2 I) which has a selective anti-muscarinic action since it exerts
gastric anti-secretory effects (M1) in doses which cause relatively
little or no effect at other cholinergic receptor sites (M2) such as
small bowel, bladder, salivary glands and pupils. In vitro studies have
confirmed muscarinic receptor sites with high (M1), medium and low (M2)
affinity for binding with pirenzepine (130,153) and the dissociation
constant differs by a factor of 40. Although in addition to the
peripheral sympathetic ganglia, M1 receptors may be found in the central
nervous system, central effects of pirenzepine are reduced by the
hydrophilic nature of the drug, causing minimal transfer across the
blood-brain barrier - levels of drug within the cerebrospinal fluid are
only 10% of those in plasma (194). Bioavailability of the drug, normally
20-30%, is reduced by around 10% when ingested with food (152).
5.2.2 Secretory Studies
Pirenzepine is a competitive antagonist of acetyl choline and, as
expected, will inhibit vagally stimulated gastric secretion (eg by
modified sham feeding) to a greater extent than direct stimulation by
secretagogues such as histamine or pentagastrin, or other exogenous
muscarinic agonists (369,213,108,127). The primary effect on acid output
is on volume rather than on acid concentration (36,125,219,340),
although two studies (311,195) demonstrated a reduction in concentration
to almost as great an extent as volume. Howden et al (174) examined the
effect of nocturnal administration of pirenzepine 100mg or 150mg on
gastric secretion. Both volume and acid concentration were significantly
inhibited by approximately 50%, although the degree of inhibition
exerted by the two doses was not significantly different. With a single
nocturnal dose of pirenzepine 50mg in duodenal ulcer patients
Corinaldesi (78) also demonstrated that volume and acid concentration
are significantly depressed, although to a lesser degree in view of the
lower dose.
Londong et al (239) examined the effect of cimetidine, pirenzepine
or a combination of the two drugs on peptone-stimulated acid secretion.
Cimetidine alone inhibited acid (mmol/3hrs) from 56.6+8.4 to 22.9+4.3
(60%) and pirenzepine alone to 24.0+5.1 (58%). In combination, however,
acid secretion was further suppressed to 6.0+1.1 (89%) suggesting a
synergistic effect. Deakin et al (90) also showed a synergistic effect
on gastric acid inhibition by combining pirenzepine and cimetidine.
5.2.3 Duodenal Ulcer Healing
A review of the literature on endoscopically controlled, double-
blind trials of pirenzepine in duodenal ulcer reveals a total of thirty
studies - sixteen placebo-controlled (three of which also with a
cimetidine limb) and fourteen cimetidine-controlled (69,14,128,
94,270,104,361,95,286,170,134,93,392,62,131,166,197,13,148,36 5,383,289,
110,82,38,273,30,233,38,109,266). The 50mg and 75mg pirenzepine groups
have been combined (three of these studies commenced with one week of
75mg daily then reduced to 50mg daily) with a four week healing rate of
58% (Table 5.2 I). This rate was increased to 68% and 77% with 100mg
and 150mg pirenzepine respectively. After four weeks, the healing rate
with cimetidine 1g daily was 73% and the placebo rate was 40%. These
findings are summarised in Table 5.2 II and depicted graphically in Fig
5.2 II. In only one trial was placebo as effective as pirenzepine (270),
but an eight week healing rate of 80% with placebo was achieved in this
study and no difference between this group and those treated with
cimetidine (86% healing) could be shown. It may well be that healing
rate improves with time as well as dose, but the available data (14/17
with 100mg) are not sufficient to support this concept.
5.2.4
Duodenal Ulcer Maintenance Treatment
459 patients with a healed duodenal ulcer have been randomised in 9
trials to either pirenzepine (30-100mg/day), cimetidine 400mg, no
therapy (70), and placebo (104,299,66,187,15,83,276,274). Although a
trend towards lower relapse rates has been established with the lower
doses, a statistically significant difference from placebo has only
been established using 100mg/day or more. Using 150mg daily Morelli et
al (274) demonstrated a significant difference in relapse rates from a
placebo- treated group when treatment was administered for two six-week
periods annually, from March-April and September-October over two years
suggesting that seasonal prophylactic therapy is efficacious. Although
the total numbers entered into maintenance trials might, at first sight,
suggest that fairly powerful predictions could be made concerning
relapse rates, the numbers are considerably reduced since many of the
studies only reported on the relapse rate at six months. The relapse
rate for those studies extending to one year was 82% on placebo, 38% on
pirenzepine (30mg, 50mg and 100mg) and 33% on cimetidine (Table 5.2
III) .
5.2.5 Refractory Ulcer
Dal Monte et al (84) identified patients who had proved
unresponsive to treatment with pirenzepine 150mg/day and cimetidine
1g/day for two months each. Seventy five patients were randomised to
three groups. After six months 85% of those receiving combined therapy
of pirenzepine 75mg and cimetidine 400mg daily had healed, as compared
with 35% of those continuing on cimetidine 1g/day and 41% of those
receiving pirenzepine 150mg/day (p < 0.01). Two studies (90,69)
demonstrating synergistic anti-secretory activity of the two drugs
therefore are particularly relevant within this context.
5.2.6 Side Effects
With a dose of pirenzepine 75mg daily, no change in the intraocular
pressure in a group of patients with open- and closed-angle glaucoma was
recorded (349,375) and no change was recorded in residual volume or
bladder emptying in a group of patients with prostatic hypertrophy
(140). Salivary secretion was reduced by 26%, however, in a group of
healthy subjects taking pirenzepine 100mg daily (196) - this figure was
even higher in an unpublished, single-dose tolerance study at McMaster
University in Canada, performed in 30 normal volunteers (141). Placebo
or pirenzepine 50mg, 100mg and 150mg were given in double-blind fashion
and dry mouth was confirmed on direct questionning by 17%, 33%, 60% and
67% respectively.
In the short term studies pirenzepine was well tolerated by most
patients and, in a post marketing surveillance (137) only approximately
2% were withdrawn from therapy. Dry mouth was the most common side
effect, with 14% of those taking 100 or 150mg daily affected. Blurring
of vision was less common - 1.1% with 100mg but increased to 5.6% with
150mg daily. Other side effects such as diarrhoea, constipation and
headache were no more common at the higher dose.
5.3 Discussion
All of the mechanism by which the various polcyclic drugs influence
gastric secretion have not been defined. However, the dissimilar
patterns of altered gastric secretion after dosing indicate that the
mechanisms of the peripheral (gastric) effects of these drugs differ, as
do their central actions, and this may be attributed, at least in part.,
to interactions with different cellular receptors (153).
Anticholinergic drugs inhibit gastric secretion (194) and, as both
trimipramine and quisultidine produce dryness of the mouth when given in
high dosage (268,50), it has been suggested that polycyclic drugs affect
gastric secretion by blocking muscarinic receptors. However, mianserin
is reported not to exert anticholinergic effects in man (60) and,
although quisultidine has also been stated to exert virtually no
anticholinergic effects, its metabolites do show affinity for muscarinic
receptors (271).
Mianserin exerts potent anti-serotonergic effects in peripheral
tissues (255) but has no effect on serotonin-induced contraction of
isolated rat gastric fundus (122) and, in any case, the effects of
serotonin on gastric secretion in man are inhibitory (192).
Several antidepressant drugs, including mianserin and imipramine,
are considered to interact with histamine H2 receptors (255) and to
exert an inhibitory effect on histamine-sensitive adenyl cyclase in
mammalian brain (202), although it has also been shown that in vivo the
cerebral H2 receptor antagonism is not significant (284). Histamine H2
receptors are important in regulating gastric secretion (355) and one
must therefore consider the possibility that some of the gastric anti¬
secretory effects of polycyclic drugs are attributable to H2 receptor
blockade. However, against this hypothesis is the finding that
quisultidine does not inhibit histmaine-stimulated gastric secretion
(271), while trimipramine actually augments histamine-stimulated
secretion in man (43), just as nocturnal secretion has been augmented by
trimipramine in the present study.
The action of pirenzepine has been more clearly defined, and is
discussed in the section on pharmacology in 5.2.1. In addition to the
selective anti-muscarinic effect, however, it has also been shown that
pirenzepine, quisultidine, mianserin and trimipramine all inhibit
calmodulin activity (265). Since the transport of calcium is involved in
gastric secretory processes (331), it may be that the polycyclic drugs
affect gastric secretion by inhibiting the movement of calcium, which is
necessary for the secretory processes of the gastric parietal and chief
cells.
In conclusion, it seems likely that the differences in gastric
actions reflect different peripheral (and perhaps also central) actions
and mechanisms. These drugs are all of real, or potential, benefit in
the treatment of ulcer disease and may provide more insight into the
mechanisms of accelerated ulcer healing.
Table 5.21 Duodenal Ulcer Healing Data
Pirenzepine vs Placebo/Cimetidine
PZP CMT Placebo F/U
Study No. Dose Heal % Dose Heal 0.o Heal % wks
mg g
Cerlek 34 50 11/15 73) 8/19 (42) 4
Barbara a) 79 75+50 23/44 52) 12/35 (34) 4
Gasbarrini 21 75+50 9/12 75) 4/9 (44) 4
Dobrilla a) 26 75+50 5/11 45) 8/15 (53) 4
Mittelstaedt 28 50 13/14 92) 1 14/14 (100) 4
Eichenberger 65 75 11/22 50) 1 16/22 (73) 12/21 (57) 4
(61 75 13/19 68) 1 19/22 (86) 16/20 (80) 8)
Sonnenberg 134 75 25/45 55) 1 34/44 (77) 25/45 (55) 4
Dobrilla b) 30 75 5/13 38) 1 10/17 (59) 4
Oselladore a ) 30 75 9/15 60) 6/15 (40) 4
417 111/191 58)
Barbara a) 92 100 32/46 70) 15/46 (32) 4
Hoffenberg 50 150+100 12/25 48) 10/25 (40) 4
Gibinski 121 100 45/58 78) 32/63 (51) 4
Brunner 254 100 81/126 64) 1 94/128 (73) 4
Giacosa 60 100 24/30 80) 1 25/30 (83) 4
Henry 50 100 14/24 64) 1 17/26 (26) 4
Jaup 75 100 27/37 73) 0.8 29/38 (76) 4
Ayoola 36 100 13/17 77) 1 15/19 (79) 4
(14/17 82) 1 17/19 (90) 8)
Guslandi 84 100 30/42 72) 1 25/42 (60) 4
822 278/405 68)
Do 38 100 14/18 78) 7/20 (35) 6
Vollenweider 33 100 14/18 78) 8/15 (54) 6
Sternini 39 100 15/19 79) 1 17/20 (85) 6
Trotman 115 100 39/53 74) 1 52/62 (84) 6
Paoluzi 96 100 15/46 33) 1 28/50 (56) 6
Fakunle 30 100 11/15 73) 1 10/15 (67) 6
351 108/169 64)
Oselladore a ) 30 150 13/15 87) 6/15 (40) 4
D'Imperio 20 150 9/10 90) 5/10 (50) 4
Benvestito 20 150 8/10 80) 3/10 (30) 4
Laugier 100 150 31/50 62) 15/50 (30) 4
Evreux 65 150 30/33 91) 1 22/32 (69) 4
235 91/118 77)
Bianchi Porro85 150 21/29 72) 1 21/28 (75) 10/28 (36) 6
Morelli 29 150 11/14 79) 2/15 (13) 6
Meunier 64 150 25/33 76) 1.2 22/31 (71) 6
178 57/76 75)
Table 5.2 II Summary of Ulcer Healing Data
Pirenzepine vs Placebo/Cimetidine
PZP CMT Placebo F/U
No. of Studies Dose Heal % Dose Heal % Heal % wks
9 75+50 111/191(58) 4
9 100 278/405(68) 1000 301/412(73) 161/398(40) 4
6 100 108/169(64) 1000 150/206(73) 27/78 (35) 6
1 100 14/17 (82) 8
5 150 91/118 (77) 4
3 150 57/76 (75) 6
Table 5.2 III Relapse on Maintenance therapy with
Pirenzepine, Cimetidine or Placebo
PZP CMT Placebo
Study No. dose relapse \ dose relapse % relapse \
wks
Eichenberger 32 30 4/9 44 400 6/11 55 8/12 67 52
Petrillo 28 50 7/15 47 9/13 69 52
Capria 60 50 5/20 25 400 4/20 20 13/20 65 26
Ireland 89 50 9/43 21 400 8/46 17 52
Cheli 32 50 3/16 19 10/16 63 26
Barberani 30 50 3/15 20 4/15 27 26
Dal Monte 54 100 15/26 58 27/28 96 52
Moshal 52 100 10/16 63 400 11/18 61 14/18 78 52
Morelli 68 150 12/35 34 for 2 6wk periods 25/33 76 32
11/51 22 4/20 20 27/51 53 26
45/106 38 25/75 33 58/71 82 52
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6 H2 RECEPTOR ANTAGONISTS
6.1 Histamine and Gastric Secretion
6.1.1 Introduction
The aim of this study was primarily to compare levels of histamine,
histidine decarboxylase, and histamine methyl transferase in gastric
fundic mucosal biopsies in patients with active duodenal ulcer disease
and non-ulcer dyspepsia, in order to assess histamine synthesis and
degradation in ulcer disease. In addition, I examined the effect of
cimetidine 1g/day and ranitidine 300mg/day for four weeks on these three
indices of histamine metabolism.
6.1.2 Patients and Methods
Biopsies were taken through an Olympus P2 gastroscope with the
standard P2 forceps from the gastric fundus of fasting patients. After
weighing, biopsies were homogenised by hand using a ground glass
homogeniser in 0.1M phophate buffer at pH 6.5 and 4 degrees C. Using a
modification (188) of the radioisotopic method of Snyder and Epps (353),
HDC concentration was then calculated in pmol/min/mg protein and
concentration of histamine in pmol/min/mg protein obtained from a
plotted standard curve. HMT was calculated using a modification (236) of
the double isotope technique of Taylor and Snyder (377) and the
concentration was expressed in pmol/min/mg protein.
The control population was derived from patients who were
undergoing gastroscopy for investigation of upper abdominal pain but in
whom the gastroscopy revealed no abnormality. All patients in the study
group had an active duodenal ulcer. Table 6.1. I indicates the
distribution of age, sex and cigarette consumption in both groups.
The following exclusion criteria were used:
1. Consumption of ulcer healing drugs within the previous three months
2. Previous gastric surgery
3. Consumption of polycyclic drugs at the time of initial endoscopy
4. Excess alcohol consumption (greater than ten pints beer/week or
equivalent)
5. Presence of chronic or debilitating disease
6. Age under 16yrs or over 65yrs
7. Gastrointestinal haemorrhage within the previous three months
Statistical analysis was undertaken with the Wilcoxon ranked sum
test, in view of the non-parametric nature of the data.
6.1.3 Results
The results are displayed in tabular form in Tables 6.1 II to IV.
There is no significant difference between the histamine concentrations
of the two combined ulcer groups and the control population. The
activity of HDC is unchanged by therapy with H2 receptor blockade, but
the concentration of histamine is increased in both treatment groups, to
a significant degree (p < 0.01) in the ranitidine group. Although the
decrease in HMT activity following four weeks of ranitidine therapy is
statistically significant (p < 0.01) there is also a significant
























Demographic profile of control and study groups
Number Age (Mean + SD) Sex Smoker
18 44 ± 11 10M 6
9 46 ± 15 7M 5
9 44+16 6M 7
Histamine Concentrations (Mean + SD) in nmol/ml
Pre Post
17.6 ± 6.3
20.1 + 7.3 28.4 ± 12.9
19.0 ± 6.1 23.4 ± 9.0
19.8 ± 6.5
HDC Activity (Mean ± SD) in pmol/min/mg protein
Pre Post
3.2 ± 3.8
2.7 + 1.9 2.0 ± 1.7
2.6 + 4.0 1.9+1.6
2.6 + 3.1







6.2.1 Introduction and Pharmacology
CM 57755 is a new, furan-based histamine H2 receptor antagonist
which was recently reported to be as potent as cimetidine in inhibiting
dimaprit-stimulated gastric secretion in cats, but to exert a more
sustained gastric inhibitory effect (235). In view of this, and the
apparent absence of any effect by this compound on the cytochrome P450
system (300), this study was designed to examine the effect of CM 57755
on nocturnal output and diurnal profile of acid and pepsin
concentration, and compare these values with the response to cimetidine
in healthy volunteers.
The molecular structure is shown in Fig 6.2 I and the molecular
weight of the compound is 408.35. Unpublished studies have shown that,
after oral administration, the drug is slowly absorbed with a bimodal
absorption profile. The first peak occurs at 1 hour and the second peak
(Cmax) at 3 hours after intake. As the second peak is higher than the
first, enterohepatic recirculation is unlikely to be an important
feature with this compound, as it is with ranitidine and cimetidine. The
elimination half life is 2 hrs, and urinary excretion of the parent drug
is approximately 50% following oral administration. As total plasma
clearance is 47 1/hr and renal clearance is 16-20 1/hr, extrarenal
(hepatic) clearance is clearly important.





Identical capsules, containing 600mg CM 57755, 600mg cimetidine or
placebo were administered under' supervision at 1800hrs with a
standardised light evening meal.
6.2.3 Results
Overnight secretion of acid was reduced from a median value of
75.4mmol to 25.4mmol by CM 57755 and to 22.9mmol by cimetidine (Table
6.2. I). The decrease from placebo values was highly significant
(p<0.01) and the inhibitory effect similar with both drugs. When acid
output was compared with placebo on an hourly basis the degree of
inhibition was significant except for the first hour and the last three
hours (Fig. 6.2. II).
The concentration of acid was more than halved (p<0.01) throughout
most of the night with both drugs, except for the first hour and the
last two hours, but did not differ from placebo at any time during the
day (Fig. 6.2 III). The differences in acid concentration were reflected
by similar increases in pH after administration of both drugs. However,
more than two consecutive pH values greater than 4.0 were observed in
only two of the ten subjects after cimetidine and in one of these two
individuals after CM 57755.
Neither nocturnal secretion of pepsin nor median peptic activity
were significantly influenced by cimetidine or CM 57755 (Table 6.2 II
and Figs. 6.2 IV and V). Total volume secreted was diminished by
approximately 40% with both drugs, although median hourly volume was
initially close to placebo values with CM 57755 (Table 6.2 III and Fig.
6.2 VI).
Table 6.2 I Nocturnal acid output (mmol/12hrs)
Subject Placebo Ciraetidine CM 57755
1 68.6 18.6 17.7
2 24.3 23.0 19.6
3 119.3 90.9 80.9
4 99.6 16.9 28.8
5 108.0 82.8 94.8
6 27.5 22.8 21.6
7 45.1 4.6 5.7
8 82.2 24.9 43.2
9 50.7 4.2 35.2
10 102.0 46.6 22.0
Mean + SD 71.9 ± 33.9 33.6 + 30.6 37.0 ± 28.9
% change 53% 49%
Median 75.4 22.9 25.4
% change 70% 66%
Table 6.2 II Nocturnal pepsin output (mg)
1 653 278 417
2 518 841 669
3 1002 1068 1212
4 924 455 720
5 936 1104 1260
6 719 588 756
7 687 168 124
8 668 939 815
9 511 215 895
10 1300 1140 908
Mean + SD 784 ± 243 680 + 385 778
% change 13% 1%
Median 703 715 786
% change 2% 12%
Table 6.2 III Nocturnal volume output (mis)
1 888 360 504
2 456 516 552
3 1068 960 888
4 1056 480 600
5 972 912 1044
6 768 492 564
7 1056 684 564
8 924 684 888
9 526 396 528
10 1020 864 744
Mean + SD 873 ± 222 593 ± 199 688
% change 32% 21%
Median 948 600 582
% change 37% 39%
Fig 6.2 I Molecular structure CM 57755
/N\
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Fig 6.2 II Median acid output (mmols)
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Fig 6.2 VI Median volume output (mis)
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6.3 ICI 162,846
6.3.1 Introduction and Pharmacology
ICI 162,846 is a new histamine H2 receptor antagonist of novel
structure (Fig 6.3 I). Animal studies have demonstrated a specific,
sustained and dose-related action on gastric secretion stimulated by
food, histamine and pentagastrin. This sustained action is not dependent
on a long plasma elimination half life which, in unpublished studies on
the dog, is less than 8 hrs. No effects have been demonstrated on either
the androgen receptor or the hepatic microsomal mixed function oxidase
system.
Studies were therefore undertaken with four different doses of this
drug in ten healthy volunteers in order to characterise the
antisecretory properties of the drug in man and to determine optimal
dosage for therapeutic trials in patients with peptic ulcer.
6.3.2 Subjects and Modifications to Methods
Ten healthy male volunteers aged 21 - 30 with a nocturnal acid
output known to be greater than 40mmol/12hrs were studied for five
periods of 24hrs, with a minimum of seven days between studies.
Four test doses (0.5, 1.0, 2.5 and 5.0mg) and placebo were each
given as a single tablet in randomised double blind fashion at 1800hrs
with a standardised light evening meal.
6.3.3 Results
All doses of the test drug were well tolerated and no side effects
were encountered. ICI 162,846" produced a dose-related inhibition of
nocturnal acid output (Fig 6.3 II). The median reduction in acid output
was significant (p<0.01) for all doses of the drug and for all time





Structural formula of [ci 162,846.
Fig 6.3 II Acid output (mmol) overnight












Fig 6.3 III Median acid output as % of placebo
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Fig 6.3 VI Median pepsin output
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periods between 2000 and 0800hrs except for the first hour and last two
hours with the lowest dose (Fig 6.3 III).
The concentration of acid was also reduced in dose-dependent manner
until 0800hrs. From 0900hrs until the end of the study none of the
values of acid concentration during tests with the different doses of
the drug differed significantly from placebo or from each other (Fig 6.3
IV). With the highest dose of the drug the gastric aspirate became
virtually anacidic throughout the night, reverting to values not
different from placebo by 0900hrs (Fig 6.3 V).
Secretion of pepsin was significantly reduced by all doses of the
drug (Fig 6.3 VI), although not as markedly as acid except with the two
highest doses, which almost abolished pepsin in seven out of the ten
subjects.
6.4 Ranitidine
6.4.1 Introduction and Pharmacology
Ranitidine is a drug which has been extensively tested both in the
laboratory, in clinical trials and on the open market (51). In summary,
ranitidine is a histamine H2 receptor antagonist with a side chain not
dissimilar to that of cimetidine but a furan rather than an imidazole
ring (Fig 6.4 I). The bioavailability, calculated from the areaunder the
curve from the oral and intravenous doses, is only around 55%,
suggesting that there is considerable first pass metabolism of the
compound on oral dosing. The mean peak serum concentration of the drug
following an oral dose occurs at between 2 and 3 hrs with a
concentration at 12 hrs sufficient to give significant inhibition of
acid. The elimination half life is around 3 hrs and renal clearance has
been calculated at just over 30 1/h.
The acute healing study was carried from 1978 - 1980, when few
reports had been published on the clinical efficacy of ranitidine in
peptic ulceration (229,33) and the optimal dose had still to be
established. Out patients with peptic ulceration attending British
military hospitals have been shown to respond poorly to cimetidine
compared with the rest of the population (154) and it was felt that this
study would provide a stringent test for the therapeutic efficacy of
what was then a fairly new H2 receptor antagonist.
Cumulative recurrence rates for duodenal ulcer range from 16% to
59%, depending on the country and centre from which the results are
reported (52). The second study assesses the value of continuing
maintenance therapy with ranitidine for longer than one year and also
examines the clinical features of the ulcer recurrence in the active and
placebo treatment groups.
6.4.2 Ulcer Healing in Service Personnel
6.4.2.1 Patients and Methods
After informed consent, eighty patients presenting to three
military hospitals with endoscopically-proven peptic ulcer were entered
into the trial. One patient had a gastric ulcer and all other patients
either had duodenal or pre-pyloric ulceration. Two patients had
previously undergone vagotomy and pyloroplasty, one had rheumatoid
arthritis and one had a past history of relapsing pancreatitis. By
double blind random allocation patients were given either ranitidine
100mg three times daily or placebo for four weeks, during which time
they were permitted access to antacids (stage I). Endoscopy was then
repeated and a further four weeks of ranitidine 100mg three times daily
given to those in whom any degree of ulceration peristed.
Following further endoscopy, the randomisation code for stage I was
broken and those with persisting ulceration divided into two groups.
Those who had already received ranitidine for eight weeks were withdrawn
from the trial. Those who had initially received placebo were given a
further four weeks (stage II) of ranitidine and re-endoscoped.
Smoking habits, alcohol consumption and the number of unconsumed
tablets were recorded at the end of each stage. Any patient drinking
more than three pints of beer or two whiskies daily was deemed to be an
"above average drinker". Routine haematology and biochemistry were
performed on entry and the end of stages I and II.
6.4.2.2 Results
Of the 80 patients who entered the trial, 2 defaulted during stage
I, one was withdrawn for non-co-operation and one was withdrawn because
his general practitioner discontinued his medication. The remaining 76
patients were available for study.
At the end of stage I, 22 of 37 patients receiving ranitidine were
asymptomatic although only 16 (73%) had healed. Of the 15 patients who
were symptomatic after four weeks of ranitidine only 4 (27%) had healed.
None of the 31 patients who were symptomatic after placebo therapy were
healed and 3 (28%) of the 8 who were asymptomatic had healed.
In the placebo group, the ulcer healed in 3 of 39 patients (7.7%).
Of 37 patients receiving ranitidine, 20 healed after four weeks of
treatment. In the second four weeks of treatment 2 patients defaulted,
leaving 15 of whom 5 healed. Of the 36 who failed to heal during
treatment with placebo, 31 completed four weeks of ranitidine and, of
these, 25 (81%) were healed. Of the remaining 6 patients, 3 completed a
further four weeks of therapy and 2 of these were healed on re-
endoscopy. The cumulative healing rates are shown in Table 6.4.2 I.
No significant relationship was demonstrated between healing rates
and age, compliance or smoking but a higher proportion of patients in
the unhealed groups consumed >3u alcohol daily (p<0.05).
One patient whose blood pressure had been recorded as normal at a
single reading before entry to the trial was found to have asymptomatic
labile hypertension at the end of stage I, during which he received
ranitidine. He remained hypertensive at the end of stage II and,
although the association with rantidine was strongly doubted, treatment
was discontinued. No biochemical or haematological abnormalities were
noted which affected clinical management in any way.
Table 6.4.2 I Cumulative Healing Rates on Ranitidine
Stage Entered Drop out Completed Healed (%) Cumulative ('
RNT in I 39 2 37 20 (54) (54)
stage I
II 17 2 15 5 (33) (69)
RNT in II 36 5 31 25 (81) (81)
stage II
II 6 3 3 2 (67) (94)
6.4.3 Ulcer Maintenance
6.4.3.1 Patients and Methods
Endoscopic confirmation, both of initial ulceration and of healing
(either with ranitidine 300mg or ciraetidine 1g daily) was obtained
before entry to the trial. Therapy was then commenced with ranitidine
150mg at night and patients reviewed at 1,2,4,6,9 and 12 months after
the start of maintenance treatment, or more frequently if necessary.
Repeat endoscopy was performed at 6 and 12 months, or earlier if
symptoms recurred. Clinical details of those entering the open
maintenance phase of the study are shown in Table 6.4.3 I.
Patients whose ulcers remained healed at the end of 12 months of
treatment were asked to take part in a further double-blind study in
which they were randomised to continuation of ranitidine 150mg at night
or identical placebo. Follow-up was similar to that during the first
year of maintenance therapy. Patients were withdrawn from the study if
they failed to follow the protocol or if they developed unwanted side
effects attributable to drug therapy.
Annual recurrence rates were calculated by life-table analysis, and
differrences in recurrence rates were assessed for statistical
significance by the log-rank test (298). Fisher's exact test was used to
compare intergroup differences in sex distribution, smoking, ulcer
complication and frequency of symptomatic and asymptomatic recurrences.
6.4.3.2 Results
Open maintenance study
One hundred and seventy one patients were entered into the study
and thirty three patients were withdrawn (Table 6.4.3 II). The
cumulative 12-month symptomatic recurrence rate was 15%, with an overall
rate of 38% when asymptomatic recurrences were included (Fig 6.4.3 II).
Of the 54 patients whose ulcers recurred during the study, 22 presented
with pain and 1 also had a haematemesis. Eighty two patients remained
endoscopically healed at the end of the year. Ulcer recurrences were
significantly commoner in smokers than in non-smokers (Table 6.4.3 III).
Double-blind study:
Forty seven patients agreed to participate in the study. Twenty one
received ranitidine and twenty six received placebo (Table 6.4.3 IV).
Two of the patients receiving ranitidine developed symptomatic
recurrence and one an asymptomatic recurrence, giving a 12-month
cumulative recurrence rate of 18% (Fig 5.4.3 III). Of the patients
receiving placebo, 16 developed symptomatic recurrence and 4 developed
asymptomatic recurrence, giving 12-month rates of 71% and 87% for
symptomatic and total recurrences respectively. Four of the sixteen
symptomatic recurrences were associated with haemorrhage.
Pattern of ulcer recurrence:
Fifty seven patients had an ulcer recurrence while receiving
ranitidine (54 in the open study and 3 in the double-blind study).
Twenty patients had ulcer recurrence after randomisation to placebo.
Asymptomatic ulcers were significantly commoner in patients receiving
ranitidine. Haemorrhage was significantly commoner in patients receiving
placebo (Table 6.4.3 V). Three of the four patients with haemorrhagic
ulcer recurrence had presented with haemorrhage before inclusion in the
maintenance studies.
While not included in the current analysis, it is worth noting
that, of the 31 patients withdrawn from the 2 studies for overt non¬
compliance or failure to attend for follow-up, 9 were eventually
referred again with symptomatic recurrence and 3 with haemorrhage.
Table 6.4.3 I Clinical details of patients entering
open maintenance study
Age (yrs.) mean + SEM 44.1 + 1.0
Male/female 112/59
Smoker/non-smoker 121/50
Median ulcer history years (range) 9 (0-55)
No. with prev. ulcer haemorrhage 30
No. with previous perforation 8
Table 6.4.3 II Reasons for withdrawal from open maintenance study
Failure to attend for follow-up 24
Overt non-compliance 7
Drug-related side-effect (diarrhoea) 1
Change of employment precluding follow up 1
Table 6.4.3 III Comparison of patients in remission
and recurrence after 12 months























Table 6.4.3 IV Clinical details of patients
randomised to ranitidine or placebo
Ranitidine Placebo
n=21 n=26
Age (mean ± SEM) 48.9+2.2 50.7±2.3
Male/female 11/10 17/9
Smoker/non-smoker 15/6 18/8
Median ulcer history 10 11
range 0-55 2-30
Prev. haemorrhage 4 8
Prev. perforation 3 1
Table 6.4.3 V Details of recurrences in patients
receiving ranitidine or placebo
Recurrences on ranitidine Recurrences on placebo
No. of patients 57 20
Symptomatic / Asymptomatic 24/33 16/4 *
Haemorrhage/uncomplicated 1/56 4/16 **
* P<0.01
** p-0.028
Fig 6.4 I Molecular structure of cimetidine and ranitidine
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6.5 Discussion
6.5.1 Histamine and Gastric Secretion
The pivotal position of histamine in the control of gastric
secretion has been underpinned by the ability of antagonists to the
histamine H2 receptor to block secretion stimulated by a number of
different pathways.
Unlike a number of other studies (249,293,98,381), a significant
difference was not detected in the levels of levels of mucosal histamine
between the pre-treatment ulcer groups and the control group. This may,
in part, be a reflection of the relatively small numbers recruited to
the study. It is not clear whether the change in HMT concentrations in
the ranitidine group after four weeks of therapy was due to the ulcer
having healed, which it did in all nine patients, or was attributable to
a direct effect of the drug. Unpublished studies, carried out in our
laboratory, demonstrated that both ranitidine and cimetidine may both
stimulate and inhibit the activity of HMT, according to the
concentration of the drug.
6.5.2 CM 57755
Despite the apparently sustained action of CM 57755 in some of the
early animal studies referred to in Ch 5.2, the results of the secretory
study indicate that 600mg of CM 57755 exerts an almost identical gastric
inhibitory effect on nocturnal secretion of acid and pepsin, and on
daytime acid concentration as the same dose of cimetidine. When assessed
by median nocturnal acid output, both drugs inhibited acid secretion by
about two thirds, while pepsin secretion was unaffected. In view of the
equipotency of the two drugs, it seems likely that CM 57755 will heal
ulcers and maintain remission in a manner similar to cimetidine. Since
the gastric inhibitory efficacy implies no therapeutic advantage or
disadvantage compared with cimetidine, any role for the new drug will be
determined by the presence or absence of unwanted side effects in man,
about which no information is yet available.
6.5.3 ICI 162,846
The second secretory study, with ICI 162,846 shows that this is a
powerful inhibitor of gastric secretion, capable of abolishing nocturnal
secretion of acid and pepsin. It has previously been shown that
nocturnal administration of cimetidine (67), ranitidine (186) and
famotidine (402) heals 70-80% of duodenal ulcers within four weeks and
that nearly all ulcers heal after eight weeks of treatment with H2
receptor antagonists administered before sleep (175). The efficacy of
nocturnal treatment is probably because these drug schedules inhibit
nocturnal gastric secretion which may, perhaps, be the principal
pathophysiologic abnormaltiy in duodenal ulcer disease (164).
The finding that increasing doses of ICI 162,846 produce a
modulated range of increases in the range of gastric secretory
inhibition is important since there is, as yet, no agreement about the
degree of interference with gastric secretion which is therapeutically
desirable. On the one hand, 0.5mg of ICI 162,846 produced a degree of
inhibition of nocturnal gastric secretion which is analogous to that
observed in response to currently available H2 receptor antagonists
(399), while a dose of 5mg resulted in inhibition which was as good as,
or better than, the inhibition achieved with 80mg of loxt.idine (54) or
20-40mg of omeprazole (401,410), the most powerful gastric inhibitors
studied to date.
While long-term treatment with cimetidine or ranitidine did not
produce neoplastic lesions in rat stomachs, long-term treatment of rats
with loxtidine and omeprazole resulted in neoplastic gastric lesions,
perhaps because the degree of inhibition produced by these latter drugs
was too severe (416,59). The search continues for drugs which can
improve ulcer healing and maintenance rates, while not posing a threat
to the integrity of the gastric mucosa in the longer term. The graded
gastric inhibition achieved with different doses of ICI 162,846 provides
a potential choice for the clinician who may require a range of
therapeutic efficacy, from partial inhibition for the healing and
maintenance of duodenal ulcers (55) to temporary complete abolition of
gastric secretion for the prevention of stress ulceration in intensive
care units (378) and of Mendelson's syndrome during labour (307).
6.5.4 Ulcer Healing in Service Personnel
In the general population, the healing rate of duodenal ulcer in
response to an optimal dose of cimetidine is approximately 80% in four
weeks, with a healing rate on placebo of about 35% (41,277). In patients
attending two British military hospitals, however, the six week heal-
rate in response to cimetidine has been reported as 21% and 27%
(154,326) and peptic ulcer remains the single most common cause of
invaliding from the British Army (365). The clinical trial of a new H2
receptor antagonist in this population therefore imposes a severe test
of the capacity of the drug to heal ulcers.
The finding of a placebo healing rate of 7.7%, only a quarter of
that found in most published series, is evidence of the relative
intractability of the ulcer diathesis in this population. Viewed in this
light the healing rates achieved are, in fact, quite impressive.
The data which might contribute to persistence of ulceration were
examined. A previous study (158) suggested an association between
ulceration, age of onset, smoking and alcohol consumption. Although this
study recruited a young population (average age 30 years), no evidence
was detected within the group of an association between age and
responsiveness to therapy. More surprisingly, no evidence was found to
support an association between smoking and resistance to treatment. It
may be that the high percentage of smokers in the study (71%) produced a
"blanket" effect, obscuring differences between the sub-groups.
Compliance has always been difficult to assess accurately in this
type of trial. Within the limits of a simple tablet count, a compliance
rate of around 90% was good compared to established standards (303), yet
no association was found. No attempt was made in this study to
differentiate the non-responders into those with and those without
symptoms when studying the effect of compliance on healing.
6.5.5 Ulcer Maintenance
Previous controlled studies have shown that maintenance treatment
with nocturnal ranitdine 150mg is as effective as cimetidine 400mg at
night (52,142) and significantly better than placebo (52,180) in
preventing duodenal ulcer recurrence during year of treatment. The
cumulative recurrence rate of 38% which is observed in this study in the
first year of open maintenance treatment is similar to reported values,
summarised in a review of studies from many centres throughout the
world, in which the average 12-month recurrence rate for all centres was
32%, with a range of 16-52% (52). Since the recurrence rate during the
second year of maintenance treatment was less than half that observed
during the first year of maintenance, it seems that ulcers that remain
healed during the first twelve months of maintenance treatment tend to
remain healed if treatment is continued.
The most significant conclusion to be derived from this study has
important implications for the management of ulcer disease. The pattern
of ulcer recurrence in patients receiving placebo is different from that
observed in patients whose ulcers recur while they are receiving
ranitidine. During active maintenance treatment ulcers which recurred
were clinically mild and often asymptomatic whereas recurrences in
patients receiving placebo were usually symptomatic and associated with
a significantly higher incidence of bleeding.
Although it might be argued that these findings could be explained
by assuming that one year of maintenance therapy with ranitidine had
worsened the natural history of duodenal ulcer disease, so that when
treatment was stopped the recurrences were more aggressive than if the
patient had received no therapy other than a short healing course of
treatment. This explanation is unlikely however, since the percentage of
ulcers which recurred during the second year of follow-up, after
randomisation to placebo, was of the same order as published values (42,
32,168,17,263,157,99,68) for ulcer recurrence in the placebo limb, after
a short course of healing therapy only.
Table 6.5 I summarises the results of seven of these studies (42,
32,168,17,263,157,99), with details of recurrences on placebo and on
cimetidine, from which it may be seen that the pattern of ulcer
recurrence during the first year after ulcer healing in patients who
received placebo or cimetidine was very similar to that found in this
study. It appears, therefore, that one year of maintenance treatment
with ranitidine has not altered the natural history of duodenal ulcer
disease. If one compares the proportion of symptomatic recurrences
in the placebo and active groups in Table 6.51, it is apparent that
asymptomatic recurrence is more common in the active treatment group.
Indeed, when the results of maintenance therapy with placebo is compared
with cimetidine 400mg or 400mg twice daily (63) the ratio of
asymptomatic to symptomatic is higher with the higher dose of cimetidine
(Table 6.5 II). The conclusion drawn, therefore, is that the high
proportion of asymptomatic ulcer recurrences in clinical trials is
predominantly a phenomenon of active therapy with H2 receptor
antagonists, although the reason(s) why these patients remain pain- or
complication-free has not yet been defined.
In addition to being symptomatic, recurrences on placebo are
significantly more likely to haemorrhage than are recurrences in
patients receiving active therapy. Since haemorrhage is an important
cause of ulcer-related mortality and morbidity (46), it is apparent that
maintenance treatment with ranitidine is safer than no therapy. The
policy of treating each ulcer relapse on an interim basis (18) does not
seem justifiable since patients are thus exposed to higher risks of
potentially fatal complications.
Table 6.5 I Recurrence rates in double-blind maintenance studies of
cimetidine and placebo in patients with duodenal ulcer
Cimetidine Placebo
Haemorrhage
Reference Symp Asymp Symp Asymp Cimetidine Pic
42 4 2 23 7 0 4
32 2 0 16 2 0 0
168 3 3 17 8 0 0
17 4 3 18 4 0 0
263 1 5 14 0 0 1
157 1 0 16 2 0 0
99 4 1 13 1 0 0
Total 19 14 117 24 0 5
Table 6.5 II Symptomatic and asymptomatic recurrrences in patients
receiving cimetidine (400mg twice daily or 400mg at
night) vs placebo in the maintenance treatment of
duodenal ulcer
Treatment Symptomatic Asymptomatic Ratio symp/asymp
Cimetidine 400mg x2/day 28 25 1.1/1
n=184
Cimetidine 400mg at night 31 14 2.2/1
n=179
Placebo 178 41 4.3/1
n=333
7 OMEPRAZOLE
7.1 Introduction and Pharmacology
Omeprazole is a substituted benzimidazole of molecular weight
345.42 and a solubility in water of 0.1mg/ml. The molecular structure is
shown in Fig 7.1 I. Omeprazole is acid labile, subject to breakdown by
gastric acid and the compound has therefore been formulated as enteric
coated granules in a gelatin-coated capsule, although this type of
preparation delays absorption (184). Metabolism is both by reduction,
forming a hydroxy compound and oxidation, which forms a sulphide and a
sulphone. Only trace amounts of the original compound are detectable in
urine and faeces.
Once absorbed, omeprazole is approximately 90% bound to plasma
proteins, with a very variable time period from administration to peak
plasma concentration (Tmax) depending mainly on the formulation in which
the drug is administered - see Table 7.2 I
An H+/K+ dependent ATPase has been shown to be localised to the
microvilli of the secretory canaliculi of the gastric parietal cell
(332) and is proposed as the likely candidate for the role of the
"proton pump". Unlike cholinergic and H2 receptor antagonists, which
modulate the behaviour of the pump indirectly, omeprazole acts upon this
enzyme system by direct inhibition (117). In isolated gland
preparations, omeprazole not only inhibits acid formation (105,118) but
also results in a reduction in the level of a phosphoenzyme intermediate
(28), indicating a direct action of omeprazole on H+/K+ ATPase.
In animal models, cimetidine inhibits histamine-stimulated acid
secretion competitively, but omeprazole inhibits acid stimulated by
histamine, pentagastrin and carbachol in a non-competitive fashion
(396). In view of these findings and the efficacy of this drug in a
number of animal models (232), studies were undertaken with this drug in
healthy volunteers and patients with peptic ulcer. At the time that
these studies were carried out the optimal therapeutic dose in duodenal
ulcer had not been established. As part of the secretory studies in
healthy volunteers the opportunity was also taken to examine the
pharmacokinetics, as this had not been undertaken with this formulation
at the dosage of 40mg or by the intraduodenal administrative route.
7.2 Pharmacokinetics
7.2.1 Introduction
One part of this study examines the effect of repeated oral dosing
on drug absorption and kinetics. The other part of the pharmacokinetic
data was obtained during pentagastrin stimulation, when a suspension of
the drug was introduced directly into the duodenum through a naso-
duodenal tube.
7.2.2 Subjects and Modifications to Methods
Table 7.2 II Demographic data
Volunteers Median Range
22 21 - 22 yrs








In the first study 6 male subjects underwent sequential venesection
on the first and seventh day after dosing with omeprazole 40mg orally
once daily before breakfast. Five mis of venous blood were withdrawn at
1.0,1.5,2.0,2.5,3.0,3.5,4.0,5.0,6.0,7.0,8.0,9.0,10.0,11.0 and 12.0 hours
after dosing. In the second study, venous blood was withdrawn from 6
healthy male subjects during the pentagastrin-stimulated secretory
studies at 0,10,20,30,45,60,90,120 and 180 mins. following intraduodenal
administration of omeprazole 40mg/80mg or placebo on three separate
occasions. The blood was placed in heparinised tubes, centrifuged and
the supernatant placed in two containers with 20 microlitres of sodium
carbonate. These containers were coded numerically in random fashion and
stored at -20 degrees C.
The frozen, coded samples were transferred to the Department of
Analytical Chemistry at Astra Pharmaceuticals in Sweden, where analysis
was undertaken by liquid chromatography and ultraviolet spectrometry
(222). Results were then forwarded to Dundee, where the code was broken
and mean values between paired samples obtained.
Plasma values thus obtained (micromol/1) were plotted on the y-
axis for each individual, against time on the x-axis. The area under the
curve (AUC), calculated using the trapezoidal rule, was then obtained at
3 (intraduodenal) and 12 (oral) hours post dose. AUC was expressed as
mean + SEM and correlated with the degree of inhibition of gastric
secretion (acid, pepsin and volume). Tmax was calculated in minutes for
each individual and a median value obtained for the group.
7.2.3 Results
Intraduodenal study - at 180 mins. after administration of 40mg the AUC
was 2.21 + 0.29 micromol/hr/1 and 5.25 + 1.47 micromol/hr/1 with 80mg
(Fig 7.2 I) .
Oral study - mean values for AUC with 40mg at day 1 and day 7 were 3.40
±2.06 and 4.72 + 1.77 micromol/hr/1 respectively.
No relationship could be demonstrated between output or percentage
inhibition of acid, pepsin or volume and either AUC or log10 AUC in the
intraduodenal study. The correlation coefficient (r) for "^inhibition and
AUC was -0.34 (acid), 0.02 (pepsin) and -0.26 (volume) with 40mg Day 1
and -0.39 (acid), 0.03 (pepsin) and 0.35 (volume) with 40mg Day 7.
In the 40mg oral dosing study, again no strong correlation was
observed between AUC and acid (r=0.72) although this value was a little
higher (0.82) with pepsin and just achieved significance at the 5%
level.
Table 7.2 I Formulation and Pharmacokinetics of Omeprazole
Study Formulation Tmax AUC
(median mins.) (mean + SEM
micromol/l/hr)
Inv. Manual (184)60mg buffered susp. 20 4.83+1.48
fasting
60mg buffered granules 20 4.34+0.58
no gelatin capsule
60mg buffered granules 38 4.30+1.25
with gelatin capsule
60mg e.c.granules 165 4.30+1.51
fasting
60mg e.c.granules 300 2.89 + 1.13
with food
Howden (171) 30mg e.c.granules Day 1 75 3.23+0.83
with gelatin capsule
30mg e.c.granules Day7 165 5.84 + 1.28
with gelatin capsule
60mg e.c.granules Day 1 105 8.82 + 1.68
with gelatin capsule
60mg e.c.granules Day 7 135 17.31+1.91
Prichard (310) 40mg e.c.granules Day 1 180 1.20 + 0.70
gelatin capsule a.m. dose
40mg e.c.granules Day 5 174 2.26 + 1.24
gelatin capsule a.m. dose
40mg e.c.granules Day 1 288 0.87 + 0.58
gelatin capsule p.m. dose
40mg e.c.granules Day 5 198 2.35 + 1.65
gelatin capsule p.m. dose
Wilson (409) 40mg suspension 7.25 2.21 + 0.29
intraduodenal
80mg suspension 15 5.25+1.47
intraduodenal
40mg e.c.granules Day 1 3.40+2.06
gelatin capsule
40mg e.c.granules Day 7 4.72+1.77
gelatin capsule





Fig 7.2 II Plasma drug levels after intraduodenal Study
PLfiSHfl DRUG LEVELS AFTER INTRADUODENAL ADMINISTRATION
Time (mlns)
7.3 Gastric Secretory Studies
7.3.1 Introduction
The effect of omeprazole on gastric secretion was studied in
healthy volunteers, during the pharmacokinetic studies, and in duodenal
ulcer patients receiving therapy. In volunteers nocturnal secretion was
studied following 30, 40 and 60mg orally and pentagastrin-stimulated
secretion was studied after 40 and 80 mg intraduodenally. The effect of
30 and 60 mg of omeprazole on overnight and pentagastrin-stimulated
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Subjects - aged 18 to 40 years
- normal physical examination and laboratory values
- no significant illness in the preceding two weeks
- no concomitant medication and no investigational drug
in the preceding four weeks
- no cardiac, renal , hepatic or gastrointestinal
disease (including a histroy of dyspepsia)
- no history of drug addiction or alcohol abuse
Patients - aged 18 to 70 years
- male
- active duodenal ulcer, verified by endoscopy
not more than 5 days previously
- no gastric or prepyloric ulcers and no pyloric stenosis
- no previous gastric surgery
- no concurrent disease which would potentially complicate
the evaluation of the drug
- no significant abnormality in laboratory values
- treatment with H2 receptor antagonists, anticholinergics
or other antisecretory drugs in the previous two weeks
- those whose ulcers had not healed during 8 weeks full therapy
with H2 receptor blocking drugs
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In summary, therefore, six healthy volunteers received received
omeprazole 30mg and 60mg daily for two treatment periods of 7 days, in
random order, separated by 15 days. Nocturnal gastric secretion was then
measured before and at the end of each treatment period. Six healthy
volunteers received omeprazole 40mg daily for one week, with nocturnal
gastric secretory studies before treatment, on day 1/2 and on day 7/8. A
third group of volunteers received placebo, 40mg or 80mg in random order
via an intraduodenal tube, after the first hour of a three hour
secretory study with intravenous pentagstrin stimulation. Twenty one
patients with active duodenal ulceration were commenced on therapy with
omeprazole 30mg or 60mg daily. Nocturnal secretory studies were
performed before, and seven days into, treatment in eleven and
pentagstrin tests were performed before and one week after (day 35) four
weeks of therapy in ten patients.
7.3.3 Results
Table 7.3.II Subjects Nocturnal Output (see also Fig 7.3 I)
Acid 30mg 40mg 60mg
mEq/hr Pre 3.3±2.9 4.3 ± 1.9 3.3+2.9
Day 1/2 0.8 ± 1.0
*(81%)
Day 7/8 1.7 ± 1.1 0.9 ± 0.4 0.9 ± 0.5
*(48%) *(79%) *(73%)
Pepsin
mg/hr Pre 50 ±16 39 ± 27 50 ± 16
Day 1/2 17 ± 26
(56%)
Day 7/8 47 ±12 34 ± 29 39 ± 23
(6%) (13%) (22%)
Volume Pre 65 ±19 69 ± 10 65 ± 19
ml/hr Day 1/2 34 ± 6
(50%)
Day 7/8 55 ± 12 41 ± 4 47 ± 23
(15%) (40%) (28%)
Table 7.3.Ill Subjects Pentagastrin Output (see also Fig 7.3 II)
Acid 1hr 2hr 3hr
Placebo 23.1+9.4 30.5 ± 11.7 25.5 ± 7.0
40mg 21.9+6.9 9.7+ 3.3 0.5 ±0.2
*(68%) **(98%)
80mg 23.9 + 8.2 6.6 ± 0.9 0
*(78%) **(100%)
Pepsin Placebo 106 + 31 134 + 80 126 + 32
40mg 138 ±60 53 ± 28 12 ± 11
(60%) **(90%)
80mg 124 ±53 29 ± 15 0
*(78%) **(100%)
Volume Placebo 246 ± 108 265 ± 117
40mg 248 ±60 47 ± 41
(85%)
80mg 277 ± 106 59 ± 44
(78%)
Table 7.3.IV Patients Nocturnal Output (see also Fig 7.3 III)
Acid 30mg 60mg
Pre 7.3 ± 5.4 6.2 ± 2.1
Day 7/8 0.4 ± 0.7 1.1 ± 0.7
*(94%) *(82%)
Pepsin Pre 51 ±15 46 ±12
Day 7/8 8 ±14 21 ±9
*(84%) *(54%)
Volume Pre 101 ± 39 77 ± 24
Day 7/8 47 ±22 46 ± 13
(53%) (40%)
Table 7.3.V Patient Pentagastrin Output
Acid 30mg 60mg
Pre 45.5 ± 4.9 37.6 ± 3.5
Day 35 32.9 ± 6.6 34.8 ± 5.0
* = p<0.05, ** = p<0.01, compared to treatment value
In the volunteers, nocturnal acid output fell by (30mg) 46%,
(40mg) 79% and (60rag) 70% after seven days and pentagastrin-stimulated
acid output by (40mg) 98% and (80mg) 100%. No clear effect was seen on
nocturnal pepsin output in volunteers but in patients values were
decreased by (30mg) 84% and (60mg) 53%. During pentagastrin stimulation
pepsin output fell by the second hour after drug administration to
(40mg) 98% and (80mg) 100% of control values.
Acid output in duodenal ulcer patients fell by (30mg) 96% and
(60mg) 81%. A further group of ten patients underwent pentagastrin tests
before and 7 days after a 28 day course of omeprazole 30mg or 60mg - no
significant difference was demonstrated following therapy.
Omeprazole was well tolerated, producing no serious adverse
experiences, changes in physical examination or laboratory values.
Fig 7.3 I Volunteers Nocturnal Output
field ( mEq/Mr)
VOLUNTEERS NOCTURNAL OUTPUT
Pepsin (rng/hr) Volume (mls/hr)
60,
Pre Day 1 Day 7 Pre Day 1 Day 7 Pre Day 1 Day 7
3.3 1.7 50 47 65 55
4.3 0.8 0.9 39 17 34 59 34 41




Fig 7.3 II Volunteers Pentagastrin Output
VOLUNTEERS PENTAGASTRIN OUTPUT
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Fig 7.3 III Patients Nocturnal Output
PATIENTS NOCTURNAL OUTPUT
field (mEq/hr) Pepsin (mEq/hr) Volume (mls/hr)
7.3 0.4 51 8 101 47





The foregoing, and other, studies in patients and healthy
volunteers have shown that omeprazole produces a dose-dependent
inhibition of basal and pentagastrin-stimulated gastric acid secretion
which is maximal after five to seven days of treatment (238,72,409).
Rapid healing of duodenal ulcers - 93% at two weeks - has been reported
with 40mg omeprazole daily (394). Eleven of the patients in the first
section of this study formed part of a larger multicentre, dose ranging
study of duodenal ulcer healing (72). The main objective was to study
the tolerance to and the efficacy of four doses of omeprazole (20,30,40
and 60mg) given once daily over four weeks to heal duodenal ulcers and
relieve symptoms. Patients in the second section, with peptic ulcers
resistant to healing with H2 recpetor antagonists, also formed part of a
larger study of seventeen patients from three different centres (384).
Really "resistant" peptic ulcers are not common but, by combining
patients from several centres, it was possible to examine whether
omeprazole offered any advantage for this therapeutic problem.
7.4.2 Acute Duodenal Ulcer Healing
7.4.2.1 Patients and Modifications to Methods
Twenty one patients with one or more duodenal ulcers, verified by
endoscopy in no more than five days before entering the study, were
randomised to therapy with omeprazole 30mg or 60mg taken once daily
before breakfast at 0800hrs. Demographic data and inclusion criteria
have been enumerated in Ch 7.2. and 7.3. Two patients had received a
course of cimetidine which had finished four and six weeks before their
initial endoscopy. Nineteen of the twenty one had taken some form of
antacid in the previous thirty days. Two patients were receiving a beta-
blocking drug for hypertension, two intermittently used a salbutamol
inhaler for asthma and one patient was an insulin-dependent diabetic.
Fourteen of the twenty one were regular smokers (mean + SEM 17 + 2/day).
Symptoms were assessed on days 0,8,15 and 29 and any adverse events
recorded. Omeprazole was administered in hard gelatin capsules
containing 30mg of omeprazole as enteric coated granules. Drug supplies
were renewed and unused capsules returned on days 8 and 15. Eleven
patients were randomised to receive 30mg daily and ten patients to 60mg
daily. Endoscopic examination of the oesophagus, stomach, first and
second parts of duodenum was carried out on days -5 to 0 and 29. Venous
blood was withdrawn and endoscopic biopsies of fundus, antrum and
duodenum were taken on both occasions. Ulcer healing was taken as
complete healing of the ulcer site.
For both the acute and the resistant ulcer healing sections the
combined results from the multicentre trial will be given in
parentheses, and the discussion sections will refer to the combined
results.
7.4.2.2 Results
All eleven (17) patients who received 30mg daily and nine (14) of
the ten (15) who received 60mg daily had healed endoscopically in four
weeks. The remaining patient, who had three ulcers at the start of the
trial, still had symptoms and persistent ulceration at four weeks. All
other patients were asymptomatic after eight days of therapy.
When the patients who received 20mg and 40mg were included (12 of
14 healed), this amounted to a total of 43 who completed the four week
course of treatment. 41 had healed although, during a subsequent six
months of follow up, 11 of 36 patients had a symptomatic endoscopically
proven relapse. The ulcers healed equally well on all four regimens and
there was no difference in the relapse rate.
Omeprazole was well tolerated, with no proven drug-related side
effects.
7.4.3 Refractory Ulcer Healing
7.4.3.1 Introduction
Rarely, patients with peptic ulceration are resistant to
conventional therapy with modern anti-ulcer drugs (417). In view of the
reports that omeprazole rapidly heals duodenal ulcers (72,149) and even
the more resistant ulcers associated with gastrinomas (226), this study
was designed to assess the therapeutic benefit, if any, that omeprazole
might confer in the situation where ulcers have persisted for three
months or more despite therapy with H2 receptor antagonists.
7.4.3.2 Patients and Methods
Four (17) patients resistant to conventional ulcer therapy were
given 40mg omeprazole orally as a morning dose for two to eight weeks
until the ulcer had healed. These patients were considered resistant
because prolonged therapy with H2 receptor antagonists for at least
three months in conventional doses, singly or in combination with other
anti-ulcer drugs, had not led to ulcer healing.
Two (10) patients had a duodenal ulcer, two (4) had a gastric ulcer
and (3) patients had a stomal ulcer after a Billroth II gastrectomy.
Ulcer size (greatest diameter) ranged from 4 to 30mm, with a median of
6mm. No patient was admitted to the trial who had been taking non¬
steroidal anti-inflammatories. All previous anti-ulcer medication was
stopped the day before starting omeprazole therapy. Endoscopy was
performed at the beginning of the study, after two weeks and, if healing
was not complete, after a further two and six weeks of therapy. Thus,
the maximum duration of therapy in any individual was eight weeks.
Patient compliance was assessed by tablet count. All patients were kept
under regular endoscopic review after healing was achieved.
7.4.3.3 Results
All therapy in the three months before the study, ulcer history and
complications are summarised in Table 7.4 I . All patients had been
treated before entry to the trial for three months, and some for more
than one year, without achieving ulcer healing.
The three stomal ulcers and two (9) out of two (10) duodenal ulcers
healed after two weeks and the remaining duodenal ulcer healed after
four weeks of therapy. Gastric ulcer healing was complete in one patient
after two weeks, in (1) patient after four weeks and in one (2) patients
after eight weeks of therapy.
Only two of the seventeen patients, both with gastric ulcers, still
had pain by day 15. One of these, patient 14, was known to suffer from
chronic pancreatitis. The other, patient 12, required four weeks of
omeprazole to heal his ulcer and his pain resolved shortly thereafter.
Capsule counts ranged from 80% to 100%. Physical examination and
laboratory studies remained normal. There were no confirmed treatment-
related side effects. Patient 5 developed epididymitis after 24 days of
treatment. Patient 12 complained of headache for two days which resolved
during continued treatment with omeprazole. Patient 14 had symptoms of
an upper respiratory tract infection associated with perioral herpes
simplex.
In eleven patients the ulcer relapsed soon after maintenance
therapy was substituted for omeprazole (Table 7.4 II). Patients 1 and
14 were rehealed with omeprazole. On 20mg omeprazole daily patient 1 had
a relapse within twelve weeks and the ulcer rehealed on 40mg omeprazole
daily in two weeks.
Patients 1 and 14 were free from relapse during continuous
treatment with 40mg omeprazole daily for more than four months. Using a
combination of ranitidine and sucralfate in patient 6, rehealing was not
achieved and a highly selective vagotomy was subsequently been
performed. Patient 16, for similar reasons, also underwent a highly
selective vagotomy.
Table 7.4. I Demographic data
Patient Site Sex Age Ulcer Complications Therapy last Cigs/day
History 3 mths (mg)
(years)





2 du M 32 15 perforation ran 300 5-10





4 du F 59 10 - ran 300 daily
5 du M 69 20 bleed cim 800 daily
6 gu(pp) F 35 13 - ran 300 15-20
7 du F 30 10 - ran 600 30
8 gu M 61 1) bleed ran 300 20
9 du M 22 5 - ran 300 -
10 stomal M 40 4 perforation ran 300-600 daily
11 stomal M 34 18 perforation ran 600 17
12 gu M 42 7 - ran 450-750 8
13 du M 43 10 vagotomy cim 800-1600 8-10 i
14 gu F 54 0.5 bleed ran 450 8-10





16 du M 49 10 - cim 1600 -
17 du M 41 20 perforation cim 1600 10-15
Table 7.4 II Healing and follow-up data
Patient Site 2 week 4 week 8 week Maintenance Duration Relapse
therapy (weeks) +/-
a healed healed - ran 600 5
1b stomal none healed - omep 20 12 +
c healed - - omep 40 >16
2 du healed healed - - >26
3 du healed healed - ran 300 3 +
pir 100
4 du healed - - ran 300 >26 ? (none)
5 du healed healed - - >16
6 gu(pp) present present healed ran 300 8 +
sue 4g
20 surgery
7 du healed healed - ran 300 48 +
8 gu healed healed - ran 300 52
9 du healed healed - ran 300 52 +
10 stomal healed - - ran 300 16 +
11 stomal healed - - ran 300 38 +
12 gu present healed - died from myocardial infarct
13 du present healed healed cim 1000 27 +
sue 4g
14a gu present present healed ran 600 4 +
b gu present present healed omep 40 >26
15 du healed healed - ran 300 20
pir 100
16 du healed - - cim 800 6 + surgery
17 du healed - - cim 800 12 +




At the 1st International Symposium on omeprazole in 1984 the
preclinical section referred to 145 published preclinical studies. Only
4 of these addressed some aspect of the safety of the drug although
reference was made during several of the presentations to studies which
had been carried out assessing the long-term toxicology of high dose
omeprazole in rats. A dose-dependent effect was seen at the two year
stage with hyperplasia of the enterochromaffin-like (ECL) cells
resulting in histological appearances similar to carcinoid. Table 7.5 I
is taken from data presented at the International Symposium by Dr R
Hakansson. The studies desribed below were initiated before the effect
on ECL cells in the rat studies had been noted.
There is no other benzimidazole currently in use in humans as an
anti-secretory agent but, in view of the effects previously reported
with cimetidine (292,294), it was thought valuable to screen omeprazole
for any similar side effects.
7.5.2 Patients and Methods
All 21 patients were male, mean age 40 years (21-66), and 14 were
smokers. These patients were diagnosed endoscopically as having an
active duodenal ulcer, and entered into a trial of treatment with
omeprazole 30mg/60mg daily for four weeks. Two biopsies were taken from
three sites - fundus, antrum and duodenum - at the time of the initial
and follow up endoscopies. One biopsy from each of the three sites was
placed in formalin and sections stained both with standard haematoxylin
and eosin, and also subsequently by Grimelsius staining to examine for
ECL cells. An assessment of the degree of inflammation was made from the
H and E sections by one single pathologist using the following scoring
system : 0=absent, 1=mild, 2=moderate, 3-marked and 4=severe. The second
of the paired biopsies was placed in gluteraldehyde and electron
microscopy carried out by the same pathologist.
Venous blood for haematology (FBC, diff and platelets) and
biochemistry (urea,electrolytes, creatinine, glucose, liver and thyroid
function, calcium, phosphate, albumin, protein and urate) was withdrawn
on days 0,14,28 and 35. In addition, blood withdrawn at that time was
analysed for serum gastrin, sex hormones (FSH, LH, testosterone and
prolactin) and lymphocyte responsiveness to PHA and Con-A. All these
analyses were undertaken in Ninewells laboratories except the gastrins,
which were measured in the Biochemical Dept. of Glasgow Royal Infirmary.
Values obtained are expressed as mean + SD, and differences between
before, during and after therapy examined by students paired 't' test.
7.5.3 Results
The mean inflammatory score for 21 patients fell from 1.7+1.2 to
0.9 + 0.9 in the duodenum (p<0.02) and from 2.0+0.8 to 1.1 +0.8 in
gastric antrum (p<0.01). The corresponding score for gastric fundus
remained with no significant change from 0.4 + 0.6 to 0.9 + 1.1.
Electron microscopy revealed no evidence of cellular damage, a
slight increase in inclusion bodies and a definite increase in tubular
vesicle formation. Grimelsius staining revealed no alteration in the
density of ECL cells.
In one patient, haemoglobin was initially depressed at 9.4g/dl but
reverted to within the normal range during the four weeks of treatment.
Tables 7.5 II,III and IV contain the values for serum gastrin, sex
hormones and lymphocyte responsiveness. Serum gastrin, although
remaining within the normal range, was significantly elevated (p<0.01)
during and following treatment with a trend to peaking during treatment
and falling after therapy was stopped, although there was no significant
difference between days 14, 28 and 35.
Table 7.5 I No. of carcinoids in rats
Male Female
vehicle 0/120 0/120
40 micro mol/kg 0/60 14/60
125 " 1/60 19/60
400 " 6/60 24/60
Table 7.5. II Gastrin (N<45pmol/l)
Pre Day 14 Day 28 Day 35
30mg 5.4+2.3 35.1 ±11.1 26.9+22.1 26.7 ±21.4
60mg 5.9 ± 3.2 27.2 ±23.1 35.7 ±20.6 18.6 ±11.2
Table 7.5 III Sex hormones
Testosterone (10-40 nmol/1)
30mg 33.1 ± 10.5 22.1 ± 7.8 21.2 ± 3.0 31.1 ± 15.1
60mg 24.1 ± 4.6 28.4 ±8.2 29.3 ±8.1 28.7 ±5.9
Prolactin <300 m.i.u./l
30mg 305 ± 301 268 ± 234 398 ± 409 266 ± 243
60mg 140 ± 36 129 ± 44 150 ± 73 183 ± 70
FSH (<40yrs 0.5 - 3.9, >40yrs 0.5 - 7.2 m.i.u./l)
30mg 3.7 ± 3.5 3.3 ± 3.7 2.7±2.6 3.6±3.0
60mg 3.3 ± 2.8 4.0±2.4 2.8 ± 1.4 4.1 ± 3.3
LH (<40yrs 0.5 - 6.8, >40yrs 1.8 - 7.0 m.i.u./l)
30mg 5.9 ± 1.9 5.9±2.4 5.4±1.2 6.3±1.5
60mg 4.4 ± 1.4 5.5 ± 1.6 5.3±1.8 4.9 ± 1.8
Table 7.5 IV Lymphocytes (65-95% cells responding)
30mg 84 ± 10 86 ± 4 84 ± 6 85 ± 3
60mg 78 ± 9 76 ± 10 77 ± 8 81 ± 7
7.6 Discussion
7.6.1 Pharmacokinetics
A number of studies have now been published about the
pharmacokinetics of omeprazole and these are summarised in Table 7.6 I.
It can be seen that several other factors, in addition to dosage level,
influence plasma drug levels achieved: formulation, pre/post - cibal,
morning or evening administration and single or multiple dosing. It has
been suggested both by Howden et al (171) and Prichard et al (310) that
omeprazole increases its own bioavailability through effecting an
increase in intragastric pH, thus reducing the breakdown of omeprazole
within the stomach.
The data from Howden et al are particularly interesting in view of
the long term effect of high doses of omeprazole in rats. In this
situation, a number of ECL - type tumours have been noted. If the data
from Howden's study are plotted with AUC against time (Fig 7.6 I) it can
be seen that the slope of the line increases as the dose is increased.
Thus higher doses of the drug achieve disproportionately higher plasma
levels.
The evidence for a positive correlation of AUC to inhibitory
effect is conflicting - the current studies and those of Howden et al do
not support this although Lind et al (238) obtained a correlation
coefficient of AUC against % inhibition of acid of 0.93. It may be, of
course, that since higher doses of omeprazole were used both in this
study and in the work by Howden, that all the points plotted were in the
upper portion of the curve.
As might be expected, absorption was most rapid when a suspension
of the drug was instilled into the duodenum. Although the addition of a
gelatin coat to the enteric coated granules slighltly delays absorption,
the ease with which the drug can be administered in this form justifies
this formulation for clinical use, particularly as good healing rates
are achieved.
7.6.2 Secretory studies
In the secretory studies, the group mean hourly acid outputs show
that omeprazole has a marked inhibitory effect on both healthy subjects
and patients. When the individual results are examined, the reduction in
acid output (with one exception) is dose-related at the 30mg and 60mg
doses in volunteers. This is in accord with another study (85) with 30mg
and 60mg, which demonstrated a reduction in mean concentration of acid
in gastric contents sampled during the night by 51% and 67%
respectively. Neither the 40mg group nor the two patient groups can be
commented on in this regard as individuals in these groups only received
therapy at a single dose level. The patients had a higher mean acid
output before therapy, which accounts for the greater percentage
inhibition, although there was no statistically significant difference
between the pre-treatment levels for the three groups.
The mechanism of reduction in gastric acid output has been
investigated by plotting the percentage of reduction in gastric acid
concentration against the percentage reduction in secretory volume for
subjects and patients (Fig 7.6 II). If the effect of omeprazole was
equal on concentration and volume then all the points would lie on the
intersecting line. As the majority of the points (17 of 22) are
displaced towards the vertical axis, it can be seen that the major
effect of omeprazole is on acid concentration with a smaller effect on
volume.
The results with pentagastrin stimulation in volunteers confirm
the observations in a previous study (238) that omeprazole is a powerful
inhibitor of gastric secretion in this setting. There is only a short
lag before the drug exerts an inhibitory effect although clearly, since
omeprazole was introduced into the duodenum, this effect must be through
a systemic action. In patients, the method of examining the effect of
omeprazole on pentagastrin stimulated secretion was not comparable but
the results clearly demonstrate a return of acid secretion to within
control levels, seven days after a twenty eight day course of therapy.
Similar studies have been carried out at other centres (72) and have
demonstrated that, at day twenty eight, acid output was inhibited with
60mg and 30mg by 94% and 81% respectively.
The effect of omeprazole on pepsin secretion is less clear. It
does appear, however, that in the study using 40mg, an early reduction
on day 1/2 is not sustained at day 7/8. This is in contrast to the
duodenal ulcer patients in whom a substantial reduction of 84% and 54%
of pre-treatment pepsin output is seen after seven days of therapy. The
fall in pepsin secretion to zero in volunteers during pentagastrin
stimulation is much more likely to be secondary to inhibition of volume
rather than any direct effect on chief cell function.
7.6.3 Ulcer healing
Since omeprazole is a powerful inhibitor of gastric secretion, the
drug has been used to heal ulcers. Omeprazole 20-60mg daily for four
weeks achieved healing in 41 of 43 patients (95%). This compares well
with other studies which report a four week healing rate of 84% with
40mg (18) and 96% with 20/60mg (149). In early open trials, both with
cimetidine and ranitidine, healing rates of 78-94% have been reported
(16,61). It is generally now accepted, however, that the proportion of
patients who heal after four weeks of H2 receptor blockers is around 70-
80% (112,7).
It is not surprising that 31% of the ulcers followed up in this
study relapsed within six months. The actual figure might well have been
higher as only symptomatic patients were re-endoscoped. Cumulative
incidences of ulcer recurrence after successful healing with H2
antagonists have been reported at between 50% and 60% (19,63,218,185).
7.6.4 Refractory ulcers
The study of patients with refractory ulcer has shown that
treatment with omeprazole 40mg daily healed peptic ulcers which had
persisted during many months of conventional therapy. These ulcers have
been defined as resistant or refractory (306,20). Resistant duodenal and
stomal ulcers healed particularly rapidly in this study during treatment
with omeprazole. In this respect, our findings compliment the study
(226) in which omeprazole has been shown to heal ulcers in patients with
the Zollinger-Ellison syndrome in whom treatment with H2 receptor
antagonists had become unsatisfactory.
Perhaps predictably, 65% of the group have so far relapsed.
Clearly, this value may alter with continued follow-up. The optimal
therapeutic management of these patients is not clear.
Recent reviews (417,9) have suggested that, when an ulcer is
resistant to one of a group of drugs, it is often necessary to change to
a drug of a different type. If medical treatment has failed to heal the
ulcer, surgical treatment, such as vagotomy plus antrectomy, is usually
required to control the ulcer disease. However, in view of the problems
associated with the surgical treatment of resistant ulcers (20,155),
effective medical therapy is preferable. Although omeprazole would
appear to be effective in this situation, the role of this compound in
the longer-term management of duodenal ulcer disease remains to be seen.
7.6.5 Safety profile
The powerful healing effects of omeprazole make it a clear
candidate drug for use in ulcer therapy. The usefulness of omeprazole is
therefore limited solely by potential toxicological problems. In this
connection, the safety studies lend further weight to the belief that
omeprazole is a safe, well-tolerated compound. In an indirect way,
however, the result which has had greatest impact on the clinical use of
this drug has been the elevation in serum gastrin. The material
presented by Dr Hakansson (Table 7.5 I) and published by his group (101)
and a separate group working in Germany (369) suggests that the effect
of omeprazole on ECL cells is related to levels of circulating gastrin.
No significant difference was present between the effect of omeprazole
30mg and 60mg on serum gastrin. However, when much higher doses of
omepraozle are used in rats, with proportionately higher serum gastrin
levels, a direct effect of gastrin on ECL cells can be seen.
Both this study and a similar study by Howden et al (172) failed to
show any alteration in sex hormone profile during omeprazole therapy. In
a volunteer study, however, it has been shown that peak Cortisol
response to ACTH is reduced during omeprazole therapy (173). Although
some drugs possessing the imidazole nucleus have been shown to inhibit
the mitochondrial cytochrome P-450 - dependent enzyme 11-hydroxylase
(206,302,392), in vitro studies (173) have shown a decrease in
deoxycortisol synthesis with omeprazole. It seems unlikely, therefore,
that the effect of omeprazole on ACTH-stimulated Cortisol is due
entirely to 11-hydroxylase inhibition.
The histological studies were carried out on patients in the
fasting, resting state. Apart from an increase in tubular vesicles, no
ultrastructural changes were noted. During histamine stimulation in the
dog, however, omeprazole causes an inrease in the number of parietal
cells with condensed mitochondria, which does not occur with ranitidine
(364). One possible interpretation of this is that the increase is a
reflection of intracellular i.e. post receptor - blockade.
Liver enzymes showed no deterioration during therapy. No effect of
omeprazole was been observed on liver enzymes in other studies either
although the effect of omeprazole on liver function, particularly
oxidative drug metabolism, has been most closely studied by Langman and
co-workers (167). These studies showed a small, dose-related inhibitory
effect of omeprazole on drug metabolism but, since this inhibiiton was
only observed in the higher dose range, it may not be relevant to
clinical use.
Fig 7.61 Increase in AUC from Day 1 to Day 7 with
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Fig 7.6 II Plot of % reduction in gastric acid concentration versus
% reduction in volume of gastric secretion - subjects and
patients after treatment with omeprazole 30mg or 60mg
























Patients with ulcers seelc medical advice mainly in order to have
pain relieved. On the other hand, doctors have two principal therapeutic
aims in ulcer disease - to relieve pain and to prevent complications. As
both pain and complications occur during ulcer relapse, it follows that
a further therapeutic objective must be to prevent relapse. The best
means of achieving these aims have not yet been defined and a discussion
therefore follows on the relief of symptoms, the healing of ulcers and
the prevention of relapse.
The efficacy of ulcer healing drugs and different therapeutic
regimens has been primarily assessed in the last decade by clinical
trials. As an adjunct to clinical trials, a number of models analysing
the impact of therapy on the natural history of ulcer disease have been
proposed. In the light of these models, and findings in practice, an
approach to ulcer therapy will subsequently be formulated. In addition,
the safety of long-term therapy of duodenal ulcer disease will be
discussed.
8.2 Pain Relief
The priority for the patient with an active ulcer is the relief of
pain. Pain relief during treatment with cimetidine occurs within a few
days of starting therapy, and failure to obtain relief should raise the
suspicion that the cause of the pain is not a duodenal ulcer (415).
Relief of pain occurs equally rapidly with bismuth subcitrate (256),
ranitidine (33), omeprazole (308) and enprostil (22).
In Ch 6.4, in a relatively resistant population, I have shown that
ranitidine still affords rapid symptomatic relief for the majority of
patients. In those who are truly resistant to H2 receptor antagonists,
it is seen in Ch 7.4 that all but two of the patients, both with gastric
ulcer, were pain free by day 15 even although the ulcer had not yet
healed in a further three patients. Similarly, the studies on
maintentance therapy in Ch 6.4 showed that persistent relief of symptoms
was achieved despite occasional endoscopically confirmed recurrence,
provided that active drug therapy was being used.
8.3 Acute Healing
Since about 70% of ulcers heal in four weeks and 95% in eight
weeks, the length of time for acute ulcer healing in clinical trials has
been set at four or eight weeks, and a refractory ulcer defined as one
which does not heal with standard therapy in two months. A linear
relationship has been demonstrated between ulcer healing and time (176).
Since it has been shown that incompletely healed ulcers relapse rapidly
(290), therapy should be continued until ulcer healing is complete and,
in the absence of endoscopic control, ulcer healing treatment should be
continued for two months.
Enprostil is not as effective as ranitidine at ulcer healing (22)
and trimoprostil only heals 62% of ulcers in a dosage of 0.75mg q.d.s.
for four weeks (6). Antacids however, even in low dosage, heal over 80%
of duodenal ulcers in four weeks if given four times daily (405), as do
both trimipramine (147) and pirenzepine (412). This value is of the same
order found during treatment with cimetidine (415), ranitidine (33) and
omeprazole (308).
In accordance with general experience, we found that 45 of 68
military patients (66%) healed after four weeks of therapy with
ranitidine (Ch 6.4) and 83% after eight weeks of treatment, despite
the relatively aggressive nature of the disease as evidenced by the
placebo healing rate of 7.7% at four weeks.
In addition to the ever-increasing range of available drugs, there
has also been a gradual shift in the recommended dosage regimens. The
initial recommended dosage schedule for cimetidine was 200mg t.i.d. and
400mg nocte (295). As a result of the finding of unsatisfactory
compliance with the qds administration of drugs, twice daily regimens
were introduced for both cimetidine and ranitidine (207,400). It is
not known which aspect of gastric secretion requires inhibition for
optimal ulcer therapy, but since one of the most prominent aspects of
the pathophysiological abnormalities associated with duodenal ulcer is
the inappropriate secretion of acid during the night, it has been
suggested that inhibition of nocturnal secretion may satisfactorily heal
ulcers. As a result, gastric inhibitory drugs have been administered at
bed time and single nocturnal doses have been shown to be equally
effective (86,138). A single dose of the powerful anti-secretory agent
omeprazole achieves healing rates as good as, or better than, with the
H2 receptor antagonists (72) and single nocturnal doses of pirenzepine
have also been advocated in an attempt to maximise ulcer healing and
minimise side effects (412).
In this connection, Howden et al (176) have analysed the results of
141 published controlled trials and obtained a significant correlation
(r=0.928) between the degree of gastric inhibition during treatment with
H2 receptor antagonists at night only, as reflected by nocturnal
intragastric acidity and ulcer healing. By stepwise linear regression,
they have determined that the contribution to ulcer healing by the
suppression of nocturnal, as opposed to diurnal, acidity is 86.1%.
The results obtained with the compound ICI 162,846 (Ch 6.3) are
therefore particularly interesting. From Howden's studies one would
predict that the marked overnight inhibition of gastric acid secretion
with this compound should afford a high ulcer healing rate. The return
to normal pH values during the day may diminish the potential toxicity
of the drug for the gastric mucosa. The gastric acid profile for CM
57755 however is remarkably similar to that obtained with cimetidine and
it is likely that this compound does not offer a significant therapeutic
advantage.
8.4 Refractory Ulcer
If ulcers do not heal within two months it may be necessary to
resort to additional or alternative therapy. Combination therapy,
particularly for ulcers which are slow to heal, is an appealing
therapeutic concept which is further discussed in Ch 5.2.5. Although
greater anti-secretory effects may be achieved (297,304,240), the
evidence that any particular combination represents a meaningful advance
in treatment is lacking. Omeprazole does represent a therapeutic
advantage in this situation, as evidenced by the findings in Ch 7.
8.5 Ulcer Relapse
Unfortunately, after healing virtually all ulcers relapse, about
80% of them within 12 to 24 months of healing. Two different regimens
have been proposed for dealing with this relapsing tendency. On the one
hand, it has been suggested that patients can be treated whenever a
relapse presents symptomatica!ly. The ulcer is then rehealed and
treatment is stopped. This type of regimen has been termed "intermittent
therapy" and is based on the assumption that presentation with
perforation or haemorrhage is uncommon. Alternatively, an attempt has
been made to keep ulcers in remission either surgically or, more
recently, by long-term continuous administration of gastric secretory
inhibitors ("maintenance therapy") in order to prevent the development
of complications.
8.6 Ulcer Models
In 1981 Pounder (305) proposed a model which analysed the
contribution of remission and relapse to the "steady state" of clinical
ulcer disease occurring during the use of three different therapeutic
approaches: administration of placebo only; maintenance treatment with
placebo or cimetidine after relapse; and of continuous maintenance
treatment with cimetidine, increasing to a healing dosage with the drug
after relapse. His findings from observing 100 patients following
healing of a duodenal ulcer led him to recommend continuous maintenance
therapy. Pounder's conclusion was in contrast to Bardhan, who also
studied approximately 100 patients and recommended that intermittent
courses of therapy (treating and healing ulcers only after a symptomatic
relapse) were best on the basis of economy and simplicity (18). The
difference between the two conclusions depends mainly on the importance
which is placed on the prevention of relapse.
Sonnenberg, in 1985, analysed the long term outcome of different
strategies in duodenal ulcer disease on the basis of a Markov chain
model (363). This hypothetical analysis, along the same lines as the
analysis by Pounder made a number of formal assumptions about ulcer
relapse, surgical referral and the fate of medically and surgically
treated patients. On the basis of the mortality and morbidity of the
current surgical and medical therapy, the analysis led him to recommend
maintenance treatment.
In view of the demonstration here in Dundee, and elsewhere, that
ulcer recurrence carries with it the risk of complications (haemorrhage
and perforation) and death, it seems that maintenance treatment is the
therapy of choice for patients with frequent relapses of ulcer disease.
Perforation and haemorrhage occur in approximately 15% (10) and 35% (11)
respectively of duodenal ulcer patients in the course of their disease
and about 2% die (47). The effect of many of the compounds examined in
this thesis on the incidence of these complications has not been
studied. It is clear, however, from the study of ranitidine in patients
whose ulcers had remained healed for one year (Ch 6.4.3) that the
incidence of haemorrhage was less in those patients who remained on
active therapy. This is also true for maintenance treatment with
cimetidine (63) since only four of four hundred patients suffered a
complication during four years of maintenance therapy (6).
8.7 Maintenance Regimens
Trimipramine reduces the relapse rate after one year of treatment
to around 30% (387) and the relapse rate of 38% with pirenzepine has
been tabulated in 5.2.III. Pirenzepine has not found widespread
popularity, however, as the therapeutic window between efficacy and
dose-related side-effects is relatively narrow.
As demonstrated in Ch 6.4.3, ranitidine given in a dose of 150mg
at night will reduce both the number of ulcer relapses. Burland, in
1980, reviewed the results with cimetidine (both in bd and single
nocturnal dose) from 22 centres and 696 patients (63). Relapse rate
after one year on active therapy was 15% with either regimen, compared
with 48% for placebo. Of the other compounds examined in the preceding
chapters, maintenance data are not available for either omeprazole or
the prostaglandins.
It is not known whether Fry's concept, that ulcer disease burns
itself out after 15 to 20 years (126) is correct or whether, as seems
likely from the age-span of the ulcer population, it is a life-long
condition. If the ulcer diathesis persists in most patients for life
then maintenance therapy must also be given for life in order to
minimise the risk of complications.
8.8 Safety of long-term duodenal ulcer therapy
No drug is currently available which will cure the ulcer
diatheses -that is, that one course of therapy of which will prevent
further relapses. As therapy may have to be continued throughout life
the safety of long-term administration clearly becomes paramount.
In addition to problems common to other groups of drugs which
are given continuously, those compounds which heal ulcers by reducing
gastric secretion - the histamine H2 receptor blockers, omeprazole,
pirenzepine and possibly some of the other polcyclic drugs - may give
rise to more specific problems. Fears have been expressed (106,102) that
prolonged suppression of acid may result in the development of gastric
carcinoma. Although these fears find support in the development of
gastric tumours in animal studies - carcinoid in rats with omeprazole
and at least four different types of neoplastic change in rat gastric
mucosa with the H2 receptor antagonists (416) there is no evidence to
link those H2 blockers in current use with an increased incidence of
carcinoma. Although both cimetidine and ranitidine can be nitrosated in
vitro, neither of these nitrosated compounds are carcinogenic (92,150).
In addition to potential carcinogenicity from nitrosated forms of the
parent compound, a second route for the formation of nitrosated
compounds has been postulated (320). It has been suggested that
persistent elevation of intragastric pH permits colonisation of the
stomach by bacteria which then reduce dietary nitrate to nitrite. This
then complexes with amino groups of food proteins to form nitroso
compounds. Although some studies have shown that the concentration of N-
nitroso compounds is increased during therapy with cimetidine (320,367),
this has not been confirmed (278) and there is no evidence that the
actual production of these compounds is increased. The post-marketing
surveillance of cimetidine (76) revealed an excess of gastric carcinoma
in the cimetidine-treated group, but this was considered due to an
excess of pre-existing malignancy in this group due to inappropriate
diagnosis.
One possible way of avoiding all such potential problems would
be to reserve drugs which act topically, such as sucralfate or even
antacid, for long-term use. Both sucralfate and many of the standard
antacid preparations contain aluminium however, some of which can be
absorbed from the gut (317,136). Some of the potential problems with
aluminium toxicity are discused in Ch 3.4
On a less speculative note, it is well recognised that a
reduction in gastric acid secretion is a predisposing factor to
infection with various enteric pathogenic bacteria (132,133,100) in
addition to some parasitic infections such as strongyloidiasis (200),
Chagas' disease (288) and schistosomiasis (107). From a metabolic point
of view, the possible nutritional consequences of hypochlorhydria
include malabsorption of iron (336) and calcium (283). These potential
dangers with cimetidine and ranitidine however, do not seem to be
borne out in clinical practice (260,261).
There are a number of other potential side effects of cimeti
dine. Alteration in renal function (261) and confusion (348) are seen
particularly in elderly patients. Loss of libido in males and
gynaecomastia have been ascribed to an anti-androgenic effect (413) and
a number of drug interactions, such as with warfarin (344), phenytoin
(280), propranolol (111) and diazepam (208). These drugs are metabolised
in part through hepatic oxidation and this effect has been linked to
partial inhibition of the cytochrome P-450 linked mono-oxygenase enzyme
system (316). These side effects are not generally observed using
maintenance therapy dosage.
Not all side effects may be harmful, since cimetidine has been
observed to increase lymhocyte responsiveness in man (294) and raise
levels of 1IDL2-C (one of the sub-fractions of high density lipoprotein
which correlates with a diminished incidence of ischaemic heart disease)
(411) .
8.9 Conclusion
The pharmacological, as opposed to the therapeutic, aim of ulcer
therapy must be directed at treating the cause of the disease. That,
clearly, is not yet possible but must be what future research is
directed toward.
In the interim, the best combination - of efficacy and safety - is,
I think, represented by the use of ranitidine 300mg at night to achieve
ulcer healing, followed by maintenance therapy of ranitidine 150mg at
night in those patients who have established recurrent disease. For
patients with refractory, or resistant, ulcers it is possible that
omeprazole or combination therapy with ranitidine and, for example,
pirenzepine, would confer benefit.
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